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UK guidelines on oesophageal dilatation in 
clinical practice
Sarmed S Sami,1 Hasan N Haboubi,2 Yeng Ang,3,4 Philip Boger,5 Pradeep Bhandari,6 
John de Caestecker,7 Helen Griffiths,8 Rehan Haidry,9 Hans-Ulrich Laasch,10 
Praful Patel,5 Stuart Paterson,11 Krish Ragunath,12 Peter Watson,13 Peter D Siersema,14 
Stephen E Attwood15
AbstrAct
These are updated guidelines which supersede the 
original version published in 2004. This work has 
been endorsed by the Clinical Services and Standards 
Committee of the British Society of Gastroenterology 
(BSG) under the auspices of the oesophageal section 
of the BSG. The original guidelines have undergone 
extensive revision by the 16 members of the Guideline 
Development Group with representation from individuals 
across all relevant disciplines, including the Heartburn 
Cancer UK charity, a nursing representative and a 
patient representative. The methodological rigour and 
transparency of the guideline development processes 
were appraised using the revised Appraisal of Guidelines 
for Research and Evaluation (AGREE II) tool.
Dilatation of the oesophagus is a relatively high-risk 
intervention, and is required by an increasing range of 
disease states. Moreover, there is scarcity of evidence in 
the literature to guide clinicians on how to safely perform 
this procedure. These guidelines deal specifically with the 
dilatation procedure using balloon or bougie devices as a 
primary treatment strategy for non-malignant narrowing 
of the oesophagus. The use of stents is outside the remit 
of this paper; however, for cases of dilatation failure, 
alternative techniques—including stents—will be listed. 
The guideline is divided into the following subheadings: 
(1) patient preparation; (2) the dilatation procedure; 
(3) aftercare and (4) disease-specific considerations. 
A systematic literature search was performed. The 
Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) tool was used to evaluate 
the quality of evidence and decide on the strength of 
recommendations made.
summAry of recommendAtions
Patient preparation
1. Predilatation investigations
1.1 Obtain biopsy specimens from all strictures 
for histological analysis to exclude ma-
lignancy and eosinophilic oesophagitis 
(GRADE of evidence: moderate; strength 
of recommendation: strong).
1.2 Repeat biopsy after cross-sectional imaging 
(computed tomography (CT) or endo-
scopic ultrasound (EUS)) in cases where 
biopsies are negative, but clinical or endo-
scopic features are atypical or suspicious 
for malignancy (GRADE of evidence: low; 
strength of recommendation: strong).
1.3 Obtain oesophageal biopsy specimens in 
young patients with dysphagia or history 
of food impaction to exclude eosinophilic 
oesophagitis (GRADE of evidence: moder-
ate; strength of recommendation: strong).
1.4 Perform barium swallow in patients with 
suspected complex strictures (such as 
post-radiation therapy or history of 
caustic injury) in order to establish the 
location, length, diameter and number 
of strictures (GRADE of evidence: low; 
strength of recommendation: strong).
2. Information and consent
2.1 Counsel all patients about the benefits and 
risks of dilatation and the likely need for 
multiple sessions before symptom resolu-
tion can be achieved (GRADE of evidence: 
low; strength of recommendation: strong).
2.2 Tailor information to the individual pa-
tient’s risk profile, based on the underly-
ing cause, location, length and diameter 
of the stricture and coexistent adverse 
health problems (GRADE of evidence: 
low; strength of recommendation: strong).
2.3 Provide all patients with written informa-
tion on oesophageal dilatation before 
the procedure and obtain written, signed 
consent. Inform patients about the perfo-
ration risk and the potential need for en-
doscopic or operative intervention should 
a perforation occur (GRADE of evidence: 
low; strength of recommendation: strong).
2.4 Inform patients— whenever appropriate—
of any alternatives to dilatation, such as 
parenteral feeding or surgery in some cas-
es (GRADE of evidence: low; strength of 
recommendation: strong).
2.5 Do not perform oesophageal dilatation in pa-
tients with active or incompletely healed 
oesophageal perforation as it may extend 
the oesophageal defect and promote me-
diastinal soiling (GRADE of evidence: low; 
strength of recommendation: strong).
2.6 Perform dilatation in patients with a re-
cent, healed perforation; recent upper 
gastrointestinal surgery; pharyngeal or 
cervical deformity; or bleeding disorders 
after careful consideration of the benefits, 
risks and alternatives of the procedure 
(GRADE of evidence: low; strength of rec-
ommendation: strong).
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3. Fasting
3.1 Advise patients to fast for at least 6 hours before the pro-
cedure in order to ensure emptying of the oesophagus 
and stomach. Patients with achalasia are likely to have 
oesophageal stasis and are therefore required to fast 
for a longer time based on the clinician’s judgement 
(GRADE of evidence: low; strength of recommenda-
tion: strong).
4. Patient premedication
4.1 Inform patients that dilatation is likely to be uncomfort-
able, in particular, when push dilators are used rather 
than dilatation balloons (GRADE of evidence: low; 
strength of recommendation: strong).
4.2 Offer patients intravenous sedation with a benzodiaze-
pine and an opioid analgesic as a minimum. Propofol 
sedation (delivered by a suitably qualified person), or a 
general anaesthetic are valid alternatives based on the 
clinician’s and patient’s preference, procedure complex-
ity as well as local availability and expertise (GRADE of 
evidence: low; strength of recommendation: strong).
the dilatation procedure
1. Personnel, training and equipment
1.1 Oesophageal dilatation should be undertaken only by (or 
under direct supervision of) an experienced operator 
who performs sufficient numbers to maintain their 
skills. The operator should be supported by at least 
two assistants (one of whom must be a trained nurse) 
in the endoscopy/radiology room (GRADE of evi-
dence: moderate; strength of recommendation: strong).
1.2 Ensure that trainees performing dilatation have adequate 
knowledge and understanding of the indications for, 
contraindications to, and complications of, this ther-
apeutic procedure. An understanding of the steps 
for recognition and management of complications is 
required. Trainees should be familiar with different 
dilatation techniques as well as alternative and com-
plementary treatment options (GRADE of evidence: 
moderate; strength of recommendation: strong).
1.3 Perform the procedure in a dedicated, fully equipped 
endoscopy room with access to X-ray screening and 
surgical support, or a similarly equipped radiological 
suite (GRADE of evidence: moderate; strength of rec-
ommendation: strong).
1.4 Units must have an agreed protocol to follow in case of 
a perforation with clear identification of a qualified 
surgeon (on or off site) to manage this complication 
in cases where luminal treatment, such as a covered 
stent, is not feasible or appropriate (GRADE of evi-
dence: low; strength of recommendation: strong).
2. Oesophageal dilators
2.1 Use either balloon or wire guided bougie dilators to 
perform oesophageal dilatation (GRADE of evidence: 
high; strength of recommendation: strong).
3. The dilatation technique
3.1 Consider limiting the initial dilatation to 10–12 mm in di-
ameter (corresponding to 30–36F) in cases of very nar-
row strictures not passable by the adult gastroscope. 
The target for filiform strictures should be even lower 
(≤9 mm)  (GRADE of evidence: very low; strength of 
recommendation: weak).
3.2 Consider using no more than three successively larger 
diameter increments in a single session for both bou-
gie and balloon dilators. The precise restriction of 
3×1 mm diameter increments is not evidence based 
(GRADE of evidence: low; strength of recommenda-
tion: low).
3.3 Use wire-guided (bougie or balloon) or endoscopically con-
trolled (balloon) techniques for all patients to enhance 
safety (GRADE of evidence: moderate; strength of rec-
ommendation: strong).
3.4 Do not use weighted (Maloney) bougies with blind in-
sertion, because safer dilators are available (GRADE of 
evidence: high; strength of recommendation: strong).
3.5 Perform dilatation without fluoroscopy for simple stric-
tures as efficacy and safety have been shown in several 
studies (GRADE of evidence: moderate; strength of rec-
ommendation: strong).
3.6 Use fluoroscopic guidance to enhance safety during 
dilatation of strictures that are either high risk (such 
as post-radiation and caustic); cannot be passed en-
doscopically and are long; angulated; or multiple 
(GRADE of evidence: moderate; strength of recommen-
dation: strong).
3.7 Perform repeat endoscopy or injection of contrast after 
dilatation in cases where perforation is suspected, to 
consider immediate treatment with a fully covered 
self-expanding metal stent (SEMS) (GRADE of evi-
dence: low; strength of recommendation: strong).
3.8 Use carbon dioxide insufflation instead of air during en-
doscopy whenever possible, in complex strictures to 
minimise luminal distension and postprocedural pain 
(GRADE of evidence: high; strength of recommenda-
tion: strong).
3.9  Consider  upper  oesophageal  sphincter  dilatation  in  the 
treatment of dysphagia with disordered upper oesoph-
ageal sphincter opening, post-cricoid web, cricopharyn-
geal bar with or without the presence of a Zenker’s 
diverticulum, or to permit passage of radiofrequency ab-
lation (RFA) catheters (GRADE of evidence: moderate; 
strength of recommendation: strong).
4. Aftercare and follow-up
4.1 Monitor patients for at least 2 hours in the recovery room 
and provide clear written instructions with advice on flu-
ids, diet and medications after the procedure (GRADE 
of evidence: moderate; strength of recommendation: 
strong).
4.2 Do not perform imaging and contrast studies routinely 
after the procedure, unless patients—during recov-
ery—develop persistent chest pain, fever, breathless-
ness or tachycardia (GRADE of evidence: very low; 
strength of recommendation: weak).
4.3 Ensure that patients are well and tolerating water on leav-
ing the hospital (GRADE of evidence: low; strength of 
recommendation: strong).
4.4 Suspect perforation when patients develop pain, breath-
lessness, fever or tachycardia. Transient chest pain is 
not uncommon following dilatation but persistent pain 
should prompt a CT scan with oral contrast to look for 
perforation (GRADE of evidence: low; strength of rec-
ommendation: strong).
4.5 Perform endoscopic re-inspection if the patient becomes 
symptomatic while in the procedure room, in order to 
assess for the presence of perforation and to undertake 
treatment which may include immediate endoscopic 
stent placement (GRADE of evidence: low; strength of 
recommendation: strong).
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4.6 Provide patients with contact information for the on-call 
team should they experience chest pain, breathlessness 
or become unwell (GRADE of evidence: low; strength of 
recommendation: strong).
4.7 Perform weekly or two-weekly dilatation sessions until 
easy  passage  of  a ≥15 mm  dilator  is  achieved  along 
with symptomatic improvement (GRADE of evidence: 
moderate; strength of recommendation: strong).
disease-specific considerations
1. Achalasia dilatation
1.1 Perform dilatation with pneumatic balloons 30–40 mm 
in diameter starting at 30 mm in the first session to 
reduce the risk of complications (GRADE of evidence: 
high; strength of recommendation: strong).
1.2 Perform a second dilatation session 2–28 days later with 
a larger size balloon of 35 mm (GRADE of evidence: 
high; strength of recommendation: strong).
1.3 Consider repeat dilatation (after the initial series) during 
follow-up to maintain symptom response (GRADE of 
evidence: high; strength of recommendation: strong).
1.4 Perform dilatation under endoscopic or fluoroscopic 
control based on clinician’s preference and local ex-
pertise (GRADE of evidence: moderate; strength of rec-
ommendation: strong).
1.5 Consider proton pump inhibitor (PPI) therapy after dil-
atation as the technique has 10–40% rate of symp-
tomatic gastro-oesophageal reflux disease (GORD) 
or ulcerative oesophagitis after treatment (GRADE of 
evidence: high; strength of recommendation: strong).
1.6 Consider performing a water-soluble contrast swallow 
after dilatation to screen for perforation, but it is not 
essential (GRADE of evidence: moderate; strength of 
recommendation: weak).
2. Peptic strictures
2.1 Offer PPI therapy to patients with GORD and dysphagia, 
as this treatment has been shown to reduce the need 
for oesophageal dilatation (GRADE of evidence: high; 
strength of recommendation: strong).
2.2 Offer PPI therapy after endoscopic dilatation for peptic 
strictures in order to reduce recurrence rate (GRADE 
of evidence: high; strength of recommendation: strong).
2.3 Offer PPI therapy rather than H2 receptor antagonists, 
which are ineffective in reducing the need for repeat 
dilatation (stricture recurrence), less effective in heal-
ing of oesophagitis and in providing symptom relief 
from GORD and dysphagia (GRADE of evidence: 
high; strength of recommendation: strong).
3. Schatzki’s ring
3.1 Do not offer dilatation for asymptomatic Schatzki’s rings 
incidentally discovered on diagnostic endoscopy or 
contrast studies (performed for unrelated indication) 
(GRADE of evidence: low; strength of recommenda-
tion: strong).
3.2 Consider exclusion of eosinophilic oesophagitis by dis-
tal, mid and proximal oesophageal biopsies in sympto-
matic Schatzki’s ring (GRADE of evidence: moderate; 
strength of recommendation: strong).
3.3 Offer a single dilatation session using graded dilatation 
to a relatively large diameter (16–20 mm) to treat dys-
phagia related to Schatzki’s ring (GRADE of evidence: 
moderate; strength of recommendation: strong).
3.4 Offer PPI therapy after dilatation, as this reduces the 
risk of relapse of Schatzki’s ring (GRADE of evidence: 
moderate; strength of recommendation: strong).
3.5 Consider electrosurgical incision as an effective alterna-
tive treatment to oesophageal dilatation for relieving 
dysphagia related to Schatzki’s ring (GRADE of evi-
dence: high; strength of recommendation: strong).
4. Post-endoscopic therapy strictures
4.1 Inform patients of up to ~50% chance of developing 
symptomatic stricture requiring endoscopic dilata-
tion after endoscopic resection (ER) either following 
endoscopic mucosal resection (EMR) or endoscopic 
submucosal dissection (ESD) in any of the following 
situations: resection size >75% of the oesophageal 
circumference; and a longitudinal resection length of 
>40 mm (GRADE of evidence: high; strength of recom-
mendation: strong).
4.2 Offer dilatation for the management of symptomatic 
post-mucosal resection strictures (GRADE of evidence: 
moderate; strength of recommendation: strong).
4.3 Inform patients that perforation rates of dilatation for 
post-ER strictures in the oesophagus can be up to 
1.1% (GRADE of evidence: moderate; strength of rec-
ommendation: strong).
4.4 Offer fully covered SEMS in carefully selected patients 
for the dilatation of refractory strictures after ER 
(GRADE of evidence: low; strength of recommenda-
tion: weak).
4.5 Consider steroid injection at the resection site or oral pred-
nisolone therapy in patients at high risk after large EMR 
or ESD to reduce stricture formation (GRADE of evi-
dence: moderate; strength of recommendation: weak).
4.6 Offer fully covered SEMS in carefully selected patients 
for the prevention of refractory strictures after ESD of 
large lesions, placing the stent at the same time as the 
first stricture dilatation (GRADE of evidence: moder-
ate; strength of recommendation: weak).
4.7 Inform patients that stricture formation requiring dilata-
tion is significantly higher in the following situations: 
after photodynamic therapy (PDT) (36%) compared 
with other forms of ablation; where ER has preced-
ed ablation (12% vs 6%); with use of higher doses of 
energy with RFA for Barrett’s oesophagus (BO); and 
after RFA for early squamous cell neoplasia (14–23%) 
(GRADE of evidence: moderate; strength of recommen-
dation: strong).
4.8 Offer dilatation in patients with clinically significant 
stricture formation after RFA, with or without pre-
vious ER (GRADE of evidence: moderate; strength of 
recommendation: strong).
4.9 Offer PPI therapy after ER or ablation to reduce stricture 
occurrence (GRADE of evidence: low; strength of rec-
ommendation: strong).
5. Eosinophilic oesophagitis
5.1 Offer dilatation along with other forms of disease mod-
ification using diet, topical steroids or other drugs 
(GRADE of evidence: moderate; strength of recommen-
dation: strong).
5.2 Start other treatments for eosinophilic oesophagitis 
(EoE) before dilatation if possible, and those may be 
continued afterwards to prevent or delay recurrence 
of symptoms (GRADE of evidence: moderate; strength 
of recommendation: strong).
5.3 Offer preliminary topical steroids followed by dilatation 
as this is more cost-effective than using dilatation alone 
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as first-line treatment (GRADE of evidence: moderate; 
strength of recommendation: strong).
5.4 Offer dilatation as first-line treatment in patients with 
acute symptoms such as food bolus obstruction and 
daily dysphagia (GRADE of evidence: moderate; 
strength of recommendation: strong).
5.5 Offer dilatation to patients with established tight stric-
ture, narrow calibre oesophagus and those who do not 
respond to diet or drugs (GRADE of evidence: high; 
strength of recommendation: strong).
5.6 Reassure patients that dilatation of EoE is no more dan-
gerous than dilatation for other oesophageal diseases, 
and the perforation rates are similar (GRADE of evi-
dence: high; strength of recommendation: strong).
5.7 Inform patients with EoE that chest pain after dilatation 
is common (GRADE of evidence: high; strength of rec-
ommendation: strong).
5.8 Inform patients that symptom response after dilatation 
usually lasts up to 1 year (GRADE of evidence: moder-
ate; strength of recommendation: strong).
5.9 Repeat dilatation  if needed  (GRADE of evidence: high; 
strength of recommendation: strong).
5.10 Consider the use of special techniques such as Endo-
FLIP and Balloon pull through to judge the optimal 
calibre and position of dilatation (GRADE of evidence: 
low; strength of recommendation: weak).
6. Postoperative strictures
6.1 Consider performing upper GI endoscopy, manometry, 
pH studies and barium swallow first in patients with 
post-fundoplication dysphagia, to understand the 
mechanism of dysphagia before dilatation or repeat 
surgery (GRADE of evidence: low; strength of recom-
mendation: weak).
6.2 Consider treatment of concurrent delayed gastric emp-
tying in order to reduce the need for redilatations 
(GRADE of evidence: low; strength of recommenda-
tion: weak).
6.3 Consider the use of balloon dilatation to 30–40 mm (as 
with achalasia) in patients with post-Nissen dysphagia 
(GRADE of evidence: low; strength of recommenda-
tion: weak).
6.4 Use steroid injections (0.5 mL aliquots of triamcinolone 
40 mg/mL to the four quadrants) to reduce the fre-
quency of repeat dilatations in anastomotic strictures 
refractory to initial dilatation approaches. This can be 
performed with a 4mm-long, 23-gauge needle imme-
diately before bougie dilatation while leaving the nee-
dle in for at least 1 min to minimise leakage of the drug 
and ensure delivery of the full dose to the target area 
(GRADE of evidence: moderate; strength of recommen-
dation: weak).
6.5 Consider using needle knife incision for anastomotic 
strictures as an alternative to dilatation (GRADE of ev-
idence: moderate; strength of recommendation: weak).
7. Post-radiation strictures
7.1 Consider a combined anterograde and retrograde dila-
tation (CARD) or rendezvous approach under general 
anaesthetic as an alternative to surgery in treatment 
of the completely obstructed oesophagus, where local 
expertise is available (GRADE of evidence: moderate; 
strength of recommendation: weak).
7.2 Use fluoroscopic guidance to assist with the rendezvous 
procedure (GRADE of evidence: moderate; strength of 
recommendation: strong).
7.3 Use a guidewire to navigate through the obstruction 
when using the CARD approach to re-establish lumi-
nal patency (GRADE of evidence: low; strength of rec-
ommendation: strong).
7.4 After gaining luminal patency using the CARD procedure, 
perform subsequent dilatation using either balloon or 
bougie (GRADE of evidence: moderate; strength of rec-
ommendation: strong).
8. Caustic strictures
8.1 Perform upper gastrointestinal tract endoscopy within 
the first 12–48 hours after caustic ingestion (GRADE 
of evidence: moderate; strength of recommendation: 
strong).
8.2 Ensure timely management of oesophageal strictures with 
dilatation as this plays a key role in affecting patient 
outcomes (GRADE of evidence: moderate; strength of 
recommendation: strong).
8.3 Consider avoiding dilatation within 3 weeks of initial 
caustic ingestion (GRADE of evidence: low; strength of 
recommendation: weak).
8.4 Consider a time interval between dilatations of <2 weeks 
(GRADE of evidence: very low; strength of recommen-
dation: weak).
9.  Refractory strictures
9.1 Inform patients about the lack of good quality evidence 
for best approach to treatment of refractory strictures 
(GRADE of evidence: low; strength of recommenda-
tion: strong).
9.2  Consider  discussion  with,  and/or  referral  to,  centres 
with expertise in treatment and follow-up of patients 
with refractory strictures (GRADE of evidence: low; 
strength of recommendation: weak).
9.3  Ensure  optimal management  of  ongoing  inflammation 
with high-dose PPI therapy before defining a stricture 
as refractory (GRADE of evidence: high; strength of 
recommendation: strong).
9.4  Consider  alternative  neuromuscular  causes  in  patients 
with ongoing dysphagia despite a seemingly adequate 
oesophageal diameter (GRADE of evidence: low; 
strength of recommendation: strong).
9.5 Use fluoroscopic guidance during dilatation of refractory 
oesophageal strictures (GRADE of evidence: very low; 
strength of recommendation: weak).
9.6 Use either bougie or balloon dilators with the decision 
individualised on a case by case basis dependent on 
the nature (length, location, cause) of the stricture 
(GRADE of evidence: low; strength of recommenda-
tion: weak). 
9.7 Use intralesional steroid therapy combined with dilata-
tion in refractory strictures with evidence of inflam-
mation (macro- or microscopically) on the assumption 
that anti-reflux therapy has been maximised previous-
ly with no benefit (GRADE of evidence: high; strength 
of recommendation: strong).
9.8 Consider  incisional  therapy  in patients with  refractory 
Schatzki’s rings and anastomotic strictures at centres 
experienced in the use of such techniques (GRADE 
of evidence: very low; strength of recommendation: 
weak).
9.9  Offer  temporary  placement  of  fully  covered  self-ex-
panding removable stents in patients where previous 
methods have been unsuccessful in maintaining ade-
quate oesophageal patency (GRADE of evidence: low; 
strength of recommendation: weak).
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9.10 The optimum duration of stent placement is usually be-
tween 4 and 8 weeks, but may vary depending on stric-
ture aetiology and length, and type of stent (GRADE 
of evidence: very low; strength of recommendation: 
weak).
9.11 Consider biodegradable stent placement to reduce the 
frequency of dilatation in selected cases (GRADE of 
evidence: low; strength of recommendation: weak).
9.12  Consider  teaching  selected,  self-motivated  patients, 
with short proximal strictures to self-bougienage 
(GRADE of evidence: very low; strength of recommen-
dation: weak).
9.13 Offer surgery to patients who do not respond or are in-
tolerant to other measures (GRADE of evidence: low; 
strength of recommendation: weak).
introduction
Oesophageal dilatation is indicated in the treatment of symp-
tomatic narrowing of the oesophagus, which may develop from 
of a wide range of anatomical and functional oesophageal disor-
ders. The formation of benign strictures of the oesophagus is the 
end result of oesophageal inflammation and ulceration, which 
leads to deposition of collagen fibres that contract over time 
and cause narrowing of the oesophageal lumen.1 Reflux-induced 
strictures used to be a frequent indication for dilatation, but 
the increasing use of proton pump inhibitors (PPIs) has led to 
a relative decrease in their incidence.2 Other important causes 
of strictures include postoperative, post-endoscopic therapy 
(such as endoscopic resection (ER) and ablation), eosinophilic 
oesophagitis, post-radiation and corrosive strictures, as well as 
rings and webs.2–4 The characteristic symptom is dysphagia to 
solids more than liquids, in contrast to those with oesophageal 
motility disorders, in whom dysphagia to both solids and liquids 
occurs.1 In the latter group, dilatation does not consistently 
improve symptoms, with the exception of achalasia for which 
oesophageal dilatation is an effective treatment.5 The primary 
aim of oesophageal dilatation is to alleviate symptoms, permit 
maintenance of oral nutrition and reduce the risk of pulmonary 
aspiration.
Guideline develoPment
This guideline is endorsed by the Clinical Services and Stan-
dards Committee of the British Society of Gastroenterology 
(BSG) under the auspices of the oesophageal section of the BSG. 
It has been extensively updated and modified since the original 
version published in 2004. The methodology and reporting of 
the guideline were developed according to recommendations by 
BSG and the National Institute for Health and Care Excellence 
(NICE) with strict adherence to the Appraisal of Guidelines for 
Research and Evaluation (AGREE II) instrument as detailed 
below.
Assessing the quality of guidelines: AGree ii instrument
The purpose of the AGREE II instrument is to provide a frame-
work to assess the quality of the guideline, provide a method-
ological strategy for its development and inform the reporting 
process of the guideline. It includes the following six domains 
which were used by our guideline development group (GDG): 
scope and purpose, stakeholder involvement, rigour of devel-
opment, clarity and presentation, applicability and editorial 
independence.
Scope and purpose
This guideline will focus on the oesophageal dilatation proce-
dure as a primary treatment for benign narrowing of the oesoph-
agus using push or balloon dilators in adult patients (≥18 years). 
Palliative treatment of malignant strictures and the use of stents 
as a primary treatment option are outside the scope of this guide-
line, but their role in dilatation failure will be discussed.6 Our 
objective is to provide a practical, evidence-based, guide for clini-
cians (gastroenterologists, upper GI surgeons, radiologists and 
non-medical endoscopists) on how to undertake oesophageal 
dilatation, as well as pre- and postprocedure considerations in 
order to maximise safety and efficacy in patients with dysphagia. 
This document is intended for use once a decision to perform 
oesophageal dilatation has been made. This decision ultimately 
resides with the caring clinician after discussion with the patient.
As the practice of pure radiological dilatation is appropriate 
in some circumstances but not always advantageous for reasons 
of convenience, the term endoscopist and endoscopic dilatation 
can sometimes be interchanged with radiologist and radiological 
dilatation throughout this document. The decision should rest 
with a team approach by endoscopists and radiologists in each 
centre.
In addition to description of the dilatation procedure, specific 
aspects of management for different types of strictures will also 
be covered. This will include peptic strictures, post-endoscopic 
therapy (such as endoscopic resection and ablation), eosinophilic 
oesophagitis, anastomotic, post-radiation and corrosive stric-
tures as well as rings and webs. The dilatation procedure for 
oesophageal achalasia will also be described.
Stakeholder involvement
The GDG included individuals who are representative of all 
the relevant professional groups, including gastroenterologists 
(including one international expert), an upper GI surgeon, a 
radiologist and a nurse endoscopist. We also included a patient 
representative (who had had several dilatations for strictures and 
a perforation) and the chair of a relevant patient charity (Heart-
burn Cancer UK). All views were actively sought and incorpo-
rated in the guideline at every stage of its development through 
regular meetings and teleconference discussions.
Rigour of development
A systematic literature search strategy was developed with the 
aid of an expert librarian. We searched MEDLINE, Embase and 
the Cochrane Central Register of Controlled Trials (CENTRAL), 
from the database inception through to 31 October 2015 and 
updated 1 January 2017. Other sources searched included refer-
ence lists of identified primary journal articles. All the guideline 
questions were designed in PICO (Problem/population, Inter-
vention, Comparator, Outcome) format and incorporated into 
an extensive search strategy (online supplementary appendix 
1) using all possible combination of search terms (both as free 
text and—where applicable—as Medical Subject Headings). No 
language limits were applied. The search results were divided 
among GDG members, who independently screened titles and 
abstracts relevant to their writing sections (two members for 
each section). Studies were included if they reported data on any 
aspect of the dilatation procedure that is relevant to the guide-
line scope and purpose.
The quality of included evidence was assessed using the Grading 
of Recommendations Assessment, Develop ment and Evalua-
tion (GRADE) system, which specifically separates the strength 
of evidence from the strength of a recommendation. While the 
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strength of a recommendation may often reflect the evidence base, 
the GRADE system allows for occasions where this is not the case—
for example, where it seems good sense to make a recommenda-
tion despite the absence of high-quality scientific evidence such as a 
large randomised controlled trial (table 1).
To achieve transparency and simplicity, the GRADE system 
classifies the quality of evidence in one of four levels—high, 
moderate, low and very low (table 1). Evidence based on 
randomised controlled trials begins as high-quality evidence, 
but our confidence in the evidence may be decreased for several 
reasons, including: study limitations; inconsistency of results; 
indirectness of evidence; imprecision; reporting bias. The 
GRADE system offers two grades of recommendations: ‘strong’ 
and ‘weak’. When the desirable effects of an intervention clearly 
outweigh the undesirable effects, or clearly do not, guideline 
panels offer strong recommendations. On the other hand, when 
the trade-offs are less certain—either because of low-quality 
evidence or because evidence suggests that desirable and unde-
sirable effects are closely balanced—weak recommendations 
become mandatory. In addition to the quality of the evidence, 
several other factors affect whether recommendations are strong 
or weak, such as: uncertainty about the balance between desir-
able and undesirable effects, uncertainty or variability in values 
and preferences and uncertainty about whether the intervention 
represents a wise use of resources.
Areas of disagreement on the recommendation grade were 
resolved by discussion, using a Delphi process. The guideline 
drafts and final manuscript were critically reviewed by an inter-
national expert (PDS) to ensure broader applicability and rigour. 
It is expected that a review and updating of this guideline will be 
required in 5 years in order to account for new developments.
Clarity and presentation
We formulated recommendations that are specific and unam-
biguous. We considered both the general procedure of dilata-
tion and specific aspects of stricture management according 
to the underlying health problem. Key recommendations are 
summarised at the beginning of the document.
Applicability
We do not expect any barriers or resource implications to the 
implementation of this guideline, because described assessment 
and treatment techniques are already being performed in clinical 
practice. We will provide a quick reference guide and suggest a 
minimum requirement for procedure documentation in order to 
facilitate audit and monitoring of outcomes in individual units.
Editorial independence
GDG members have declared their conflicts of interest. The 
views of any funding body did not influence the content of this 
guideline.
PAtient PrePArAtion
Oesophageal dilatation is best undertaken as a planned proce-
dure in patients who have been appropriately investigated, 
prepared and consented. An assessment of the patient’s nutri-
tional status and referral to a dietician should also be considered.
Predilatation investigations
(a) Should all strictures be biopsied before dilatation?
 ► Obtain biopsy specimens from all strictures for histo-
logical analysis to exclude malignancy and eosinophilic 
oesophagitis7–9 (GRADE of evidence: moderate; strength of 
recommendation: strong).
Obtaining a definitive diagnosis before dilatation is desirable, 
because this will influence the overall management and estimation 
of perforation risk.8–10 Oesophageal biopsy samples can be safely 
obtained immediately before oesophageal dilatation7; however, 
if the stricture is tight or when the endoscopic features suggest 
malignancy, the results of biopsies are best awaited.4
 ► Repeat biopsy after cross-sectional imaging (CT or with 
endoscopic ultrasound (EUS) in cases where biopsies are 
negative, but clinical or endoscopic features are atypical 
or suspicious for malignancy11 (GRADE of evidence: low; 
strength of recommendation: strong).
EUS may be a more sensitive test than CT, but passage of the 
EUS probe is often not successful in the case of a stricture.11
 ► Obtain oesophageal biopsy specimens in young patients with 
dysphagia or history of food impaction to exclude eosino-
philic esophagitis8 9 (GRADE of evidence: moderate; strength 
of recommendation: strong).
(b) Are there any other recommended tests?
 ► Perform barium swallow in patients with suspected complex 
strictures (such as post-radiation therapy or history of caustic 
injury) in order to establish the location, length, diameter 
and number of strictures12 13 (GRADE of evidence: low; 
strength of recommendation: strong).
Barium swallow is also useful to evaluate the presence of asso-
ciated pathology such as an oesophageal diverticulum or a hiatus 
hernia.12 13 This information will aid selection of the dilating 
technique, estimation of the number of sessions required and 
counselling the patient about the expected risks.13
information and consent
The overall consent process should be in line with the published 
BSG guidance.14
(a) What information should patients be given?
 ► Counsel all patients about the benefits and risks of dilatation 
and the likely need for multiple sessions before symptom 
resolution can be achieved (GRADE of evidence: low; 
strength of recommendation: strong).
 ► Tailor information to the individual patient’s risk profile, 
based on the underlying cause, location, length and diameter 
table 1 An overview of the GRADE system278
GrAde—strength of evidence GrAde—strength of recommendation
High quality: Further research is very unlikely to change our confidence in the estimate 
of effect
The trade-offs: Taking into account the estimated size of the effect for main outcomes, 
the confidence limits around those estimates and the relative value placed on each 
outcome
Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate
The quality of the evidence
Low quality: Further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate
Translation of the evidence into practice in a particular setting: Taking into consideration 
important factors that could be expected to modify the size of expected effects
Very low quality: Any estimate of effect is very uncertain Uncertainty about the baseline risk for the population of interest
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of the stricture and coexistent adverse health problems 
(GRADE of evidence: low; strength of recommendation: 
strong).
Our patient representatives suggested that the use of a 
diagram to illustrate the location, length and shape of the stric-
ture is desirable to enhance the patient’s understanding of the 
procedure. Moreover, the presence of a relative or a caregiver 
should be encouraged if deemed appropriate during the consent 
process.
 ► Provide all patients with written information on oesopha-
geal dilatation before the procedure and obtain written, 
signed consent. Inform patients about the perforation risk 
and the potential need for endoscopic or operative interven-
tion should a perforation occur (GRADE of evidence: low; 
strength of recommendation: strong).
 ► Inform patients— whenever appropriate—of any alterna-
tives to dilatation, such as parenteral feeding or surgery in 
some cases (GRADE of evidence: low; strength of recommen-
dation: strong).
(b) What are the possible complications?
Complications include pulmonary aspiration, bleeding, perfo-
ration, risks of sedation and chest pain15; the last of these being 
more common in patients with eosinophilic oesophagitis.16 17 A 
UK regional audit published in 1995 reported an overall perfo-
ration rate of 2.6% with a 30-day mortality of 1%.10 Perfora-
tion was less common following dilatation of benign strictures 
(1.1% with a mortality of 0.5%) than following dilatation and/
or intubation of malignant strictures (6.4% with a mortality of 
2.3%).10 The risk of perforation was greater with less experi-
enced endoscopists (performed <500 previous diagnostic endos-
copies).10 Hernandez et al reported a perforation rate of 4 out 
of 348 procedures (1.1%); however, all these four perforations 
occurred when Maloney dilators (non-wire guided) were passed 
blindly into complex strictures. No perforations occurred with 
Savary-Gilliard (wire-guided) and balloon dilators.12 Hagel et al 
reported the most recent large retrospective case series of 1497 
procedures on 368 patients over a 10-year period. Operators 
used Savary-Gilliard bougies (Cook Medical, Bloomington, 
Indiana, USA) or through the scope (TTS) balloons (Controlled 
Radial Expansion, CRE, Boston Scientific Ltd, Cork, Ireland 
and Eclipse Wire Guided Balloon Dilators, Cook Ireland Ltd, 
Limerick Ireland). Eight perforations (0.53%) occurred in malig-
nant, post-radiation or caustic strictures. No perforations were 
reported in other types of strictures, such as peptic, postopera-
tive and eosinophilic oesophagitis.18
The reported risk of perforation in achalasia has varied widely 
across studies from 0% to 8% (2–4% in most studies) with a 
mortality of 0–1%.19 20 Katzka et al19 pooled data from all 25 
studies in the literature and reported a perforation rate of 2%; 
however, the balloon size, pressure, dilatation times and single 
or multiple dilatations varied in almost every study. The perfo-
ration rate is lower with a graded approach to balloon dilatation 
and in experienced hands.20
(c) What are the contraindications/cautions for stricture 
dilatation?
 ► Do not perform oesophageal dilatation in patients with 
active or incompletely healed oesophageal perforation as it 
may extend the oesophageal defect and promote mediastinal 
soiling3 4 (GRADE of evidence: low; strength of recommen-
dation: strong).
 ► Perform dilatation in patients with a recent, healed perfo-
ration; recent upper gastrointestinal surgery; pharyngeal 
or cervical deformity; or bleeding disorders after careful 
consideration of the benefits, risks and alternatives of the 
procedure3 4 (GRADE of evidence: low; strength of recom-
mendation: strong).
Dilatation may be performed in patients who are having 
concurrent radiotherapy.3 4
fasting
 ► Advise patients to fast for at least 6 hours before the proce-
dure in order to ensure emptying of the oesophagus and 
stomach. Patients with achalasia are likely to have oesopha-
geal stasis and are therefore required to fast for a longer time 
based on the clinician’s judgement3 4 (GRADE of evidence: 
low; strength of recommendation: strong).
Patient premedication
 ► Inform patients that dilatation is likely to be uncomfortable, 
in particular, when push dilators are used rather than dilata-
tion balloons (GRADE of evidence: low; strength of recom-
mendation: strong).
 ► Offer patients intravenous sedation with a benzodiazepine 
and an opioid analgesic as a minimum. Propofol sedation 
(delivered by a suitably qualified person), or a general anaes-
thetic are valid alternatives based on the clinician’s and 
patient’s preference, procedure complexity, as well as local 
availability and expertise (GRADE of evidence: low; strength 
of recommendation: strong).
Patients taking anticoagulants or antiplatelet agents and 
those at risk of endocarditis
UK-based clinicians must adhere to the BSG and NICE guide-
lines on management of anticoagulation and antibiotic prophy-
laxis during endoscopy.21 22 Clinicians in other countries should 
follow the corresponding guidelines in their country or region 
of practice.22–24
the dilAtAtion Procedure
Personnel, training and equipment
(a) Who should perform dilatation?
 ► Oesophageal dilatation should only be undertaken only by 
(or under direct supervision of) an experienced operator 
who performs sufficient numbers to maintain their skills. 
The operator should be supported by at least two assis-
tants (one of whom must be a trained nurse) in the endos-
copy/radiology room4 25 26 (GRADE of evidence: moderate; 
strength of recommendation: strong).
The specific number of dilatation procedures required 
each year to maintain the operator’s skills remains unknown. 
It is good practice for independent operators to audit their 
outcomes and be regularly involved in the care of patients with 
upper GI disorder. Professional bodies such as Joint Advisory 
Group on Gastrointestinal Endoscopy (JAG) may define the 
suitable number of procedures for training and maintenance of 
practice standards.
 ► Ensure that trainees performing dilatation have adequate 
knowledge and understanding of the indications for, 
contraindications to, and complications of, this therapeutic 
procedure. An understanding of the steps for recognition 
and management of complications is required. Trainees 
should be familiar with different dilatation techniques as 
well as alternative and complementary treatment options27 
(GRADE of evidence: moderate; strength of recommenda-
tion: strong).
It is estimated that less experienced endoscopists (who 
have performed fewer than 500 diagnostic upper endoscopy 
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procedures) are four times more likely to cause a perforation 
than their more experienced colleagues.10 In the UK, the JAG 
stipulates that training on therapeutic endoscopy should be 
undertaken only after competency in diagnostic procedures 
is achieved (minimum of 300 procedures) and the former 
should take place under direct supervision.27 No formal 
guidelines exist for interventional radiologists, but a similar 
level of experience in diagnostic and interventional proce-
dures is recommended. Close collaboration of the radiolo-
gists with interventional endoscopists and upper GI surgeons 
is essential for the appropriate management of complications.
Appropriate staffing and equipment are important for the 
provision of safe and successful therapeutic endoscopy 
procedures. Poor staffing levels are associated with worse 
outcomes from dilatation.10 Procedural assistants should be 
familiar with the dilatation equipment and capable of helping 
the operator in cases of an emergency. Qualified radiogra-
phers must be present when the procedure is performed 
under X-ray screening.4 10 25
(b) Where should the procedure be performed?
 ► Perform the procedure in a dedicated, fully equipped endos-
copy room with access to x-ray screening and surgical 
support,10 25 or a similarly equipped radiological suite 
(GRADE of evidence: moderate; strength of recommenda-
tion: strong).
 ► Units must have an agreed protocol to follow in case of a 
perforation with clear identification of a qualified surgeon 
(on or off site) to manage this complication in cases where 
luminal treatment, such as a covered stent, is not feasible or 
appropriate6 10 (GRADE of evidence: low; strength of recom-
mendation: strong).
Access to radiographic screening must be available to assist 
dilatation if there are difficulties in passing a guidewire or 
balloon catheter through the stricture.25 When a perforation 
occurs, prompt treatment should be started and the relevant 
surgical team must be informed immediately.25
oesophageal dilators
There are two types of oesophageal dilators: the push (bougie) 
dilator and the balloon dilator.
Push dilators
Push dilators are either wire guided (metal olives, Celestin-type 
dilators or polyvinyl bougies) or non-wire guided (tungsten-filled 
weighted rubber bougies).28
Several models of wire-guided bougie dilators are avail-
able. The Savary-Gilliard (Cook Medical, Winston-Salem, 
North Carolina, USA) dilators are polyvinyl chloride, 
latex-free cylindrical solid tubes with a central channel to 
accommodate the guidewire. They are the most widely used 
(5–20 mm diameter). Each dilator has a 20 cm tapered tip 
and a radio-opaque band at the widest point of the dilator 
to aid radiological localisation. American Dilatation System 
(ConMed, Utica, New York, USA) and SafeGuide dilators 
(Medovations, Milwaukee, USA) are similar, but are totally 
radio-opaque throughout their length.28 Bougie dilators 
have external markers indicating the distance from the tip 
(American System) or from the point of maximal diameter 
(Savary-Gilliard) or both (SafeGuide). The InScope Optical 
Dilator (Ethicon Endosurgery Inc, Blue Ash, Ohio, USA) is 
a flexible, transparent, bougie with three dilating segments 
fitted over a standard endoscope to allow sequential dilata-
tion under direct vision, but data on its efficacy are scarce.29 
The Eder-Puestow dilators comprise a series of graduated 
metal  olives  (6.6–19.3 mm  diameter)  mounted  on  a  flex-
ible shaft. At one time, this was the only system available 
for dilating complex or resistant strictures, but is now rarely 
used.
Non-wire-guided weighted bougies are passed blindly after 
the application of local anaesthetic while the patient is in a 
sitting position. This approach has been used for self-dilatation 
in carefully selected patients, but it is seldom used now owing to 
concerns about safety.28 The Maloney dilator was the most 
commonly used. It has a tapered tip and is available in multiple 
sizes. Older versions were internally weighted with mercury, 
which has now been replaced by tungsten because of concerns 
about leakage and disposal of mercury.
Balloon dilators
Through the scope (TTS) balloon dilators are available in 
a variety of designs, lengths and diameters from various 
manufacturers. They are designed to pass through the endo-
scope with or without wire guidance so that dilatation can be 
observed. The balloon is made of low-compliance, inflatable, 
thermoplastic polymers that allow uniform and reproducible 
expansion to the specified diameter. Most balloons allow for 
sequential expansion to multiple diameters. Larger ranges of 
wire-guided balloons are available for non-endoscopic dila-
tation under fluoroscopy. The balloon size needs to be care-
fully matched to the size of the stricture (see below). Dilating 
balloons are expanded by pressure injection of liquid (eg, 
water, radio-opaque contrast) using a handheld accessory 
device. Inflation with radio-opaque contrast allows for fluo-
roscopic observation. The hydraulic pressure of the balloon 
is monitored manometrically to gauge the radial expansion 
force. Balloon dilators are single-use only.28
For achalasia dilatation, large-diameter (30, 35 and 40 mm) 
polyethylene balloon dilators with radio-opaque markers are 
used.28 They are all wire-guided, single use, and do not pass 
through the endoscope. They are positioned using fluoro-
scopic guidance, and balloon insufflation pressure is monitored 
manometrically.28
(a) Is there a difference in clinical outcomes between balloons 
and bougie dilators?
 ► Use either balloon or wire-guided bougie dilators to perform 
oesophageal dilatation30–32 (GRADE of evidence: high; 
strength of recommendation: strong).
There is no difference in clinical outcomes—in particular, 
safety and efficacy, between wire-guided bougie and balloon 
dilators. Hence the choice should be based on clinician’s 
preference, local expertise, equipment availability, cost and 
the availability of robust methods of decontamination of 
reusable medical devices as many push dilators are not single 
use.30–32
Three randomised controlled trials compared these two 
techniques and found no difference in efficacy for dysphagia 
relief or safety at 1 year. Another retrospective study 
compared Maloney, balloon-type (both the hydrostatic and 
pneumatic type) and Savary-Gilliard dilators in 102, 156 and 
90  sessions,  respectively.  The  risk  of  oesophageal  perfora-
tion was higher with Maloney dilators when passed, blindly, 
into complex strictures; hence they should be avoided in 
these cases, and in patients with a tortuous oesophagus and 
large hiatus hernia.12 Savary-Gilliard and balloon dilators 
are currently the most frequently used.28 Although balloon 
dilators allow the procedure to be performed under direct 
vision, they are more costly than push dilators28 but there 
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is no direct cost-effectiveness comparison of the two tech-
niques in clinical practice.
the dilatation technique
This section describes the general technique of benign stricture 
dilatation. Achalasia dilatation and disease-specific consider-
ations will be discussed in subsequent sections.
Strictures can be simple or complex.33 34 Simple strictures are 
short (<2 cm), concentric, straight, and allow the passage of a 
normal diameter endoscope.33 34 Examples include Schatzki’s 
rings, oesophageal webs and peptic strictures.33 34 Overall, one 
to three dilatation sessions are sufficient to relieve dysphagia 
in simple strictures. Only 25–35% of patients require addi-
tional sessions, with a maximum of five dilatations in >95% of 
patients.35 Complex strictures are usually longer (≥2 cm), angu-
lated, irregular or have a severely narrowed diameter.33 34 These 
are more difficult to treat and have a tendency to be refractory 
or to recur despite dilatation.
(a) What size dilator should be initially chosen?
The initial dilator choice should be based on the known or esti-
mated stricture diameter, length and the underlying pathology.
 ► Consider limiting the initial dilatation to 10–12 mm in diam-
eter (corresponding to 30–36F) in cases of very narrow stric-
tures not passable by the adult gastroscope. The target for 
filiform strictures should be even lower (≤9 mm) (GRADE 
of evidence: very low; strength of recommendation: weak).
(b) What is the recommended number of dilatations or size 
increments per session?
 ► Consider using no more than three successively larger 
diameter increments in a single session for both bougie and 
balloon dilators. The precise restriction of 3×1 mm diameter 
increments is not evidence based3 4 36 (GRADE of evidence: 
low; strength of recommendation: low).
Although a ‘rule of three’ is recommended by many prac-
tice guidelines and authorities,3 4 no studies have demonstrated 
improvement in safety or efficacy with this approach. On the 
other hand, a recent retrospective study showed that non-adher-
ence to the rule of three did not appear to increase the risk of 
adverse events, particularly perforation, after oesophageal dilata-
tion using bougie dilators, except for malignant strictures.36 For 
very tight or long strictures, it may be safer to limit the initial dila-
tation to one or two size increments (2×1 mm) only. Conversely, 
larger increments may be safely used (4×1 mm or 3×2 mm) in 
less tight strictures or in those which have completely recurred 
after the first dilatation session.37 Patients usually need several 
sessions to achieve resolution of dysphagia and they should be 
informed of this possibility before the first procedure.
(c) The need for wire guidance or endoscopic control?
 ► Use wire-guided (bougie or balloon) or endoscopically 
controlled (balloon) techniques for all patients to enhance 
safety18 38–40 (GRADE of evidence: moderate; strength of 
recommendation: strong).
 ► Do not use weighted (Maloney) bougies with blind insertion, 
because safer dilators are available41 (GRADE of evidence: 
high; strength of recommendation: strong).
(d) What is the role of fluoroscopy in stricture dilatation?
 ► Perform dilatation without fluoroscopy for simple stric-
tures as efficacy and safety have been shown in several 
studies18 38–40 (GRADE of evidence: moderate; strength of 
recommendation: strong).
 ► Use fluoroscopic guidance to enhance safety during dilata-
tion of strictures that are either high risk (such as post-ra-
diation and caustic); cannot be passed endoscopically and 
are long; angulated; or multiple18 38–40 (GRADE of evidence: 
moderate; strength of recommendation: strong).
The use of radiographic screening in non-simple strictures 
gives additional assurance and control of the dilatation process. 
During wire-guided dilatation, it demonstrates that the wire has 
passed the stricture, and kinking of the wire has not occurred 
within or distal to the stricture. Fluoroscopy also shows that the 
dilator is following the line of the oesophageal lumen. During 
balloon dilatation, it indicates whether the balloon has slipped 
during inflation and whether obliteration of the stricture waist 
has occurred.3 4
Radiographic screening is particularly helpful when the stric-
ture is tortuous or complex or associated with a large hiatus 
hernia or a diverticulum. It may also be of value when the 
guidewire meets resistance during passage through the stricture 
or when an adequate length of wire cannot be passed distal to 
the stricture. Although comparative trials are not available, the 
selective use of radiological screening appears safe and effective 
and is supported by extensive clinical experience.42 43 The use of 
small calibre gastroscopes should also be considered in narrow 
strictures.
 ► Perform repeat endoscopy or injection of contrast after dila-
tation in cases where perforation is suspected, to consider 
immediate treatment with a fully covered self-expandable 
metal stent6 (GRADE of evidence: low; strength of recom-
mendation: strong).
 ► Use carbon dioxide insufflation instead of air during endos-
copy whenever possible, in complex strictures to minimise 
luminal distension and postprocedural pain44 (GRADE of 
evidence: high; strength of recommendation: strong).
Upper oesophageal sphincter disturbances, including motor 
disorders and mechanical disorders, can result in symp-
toms of dysphagia.45 Pathologies associated with disordered 
neurally mediated opening of the upper oesophageal sphincter, 
including oculopharyngeal muscular dystrophies, may be 
amenable to dilatation to relieve symptoms.46 Furthermore, 
while a cricopharyngeal bar is often an incidental radiological 
finding in cricopharyngeal fibrosis, treatment of associated 
dysphagia by both balloon and bougie dilatation methods can 
be successful.47
 ► Consider upper oesophageal sphincter dilatation in the 
treatment of dysphagia with disordered upper oesophageal 
sphincter opening, post-cricoid web, cricopharyngeal bar 
with or without the presence of a Zenker’s diverticulum, or 
to permit passage of radiofrequency ablation (RFA) cathe-
ters45–53 (GRADE of evidence: moderate; strength of recom-
mendation: strong).
Aftercare and follow-up
(a) Postprocedure and discharge instructions
 ► Monitor patients for at least 2 hours in the recovery 
room and provide clear written instructions with advice 
on fluids, diet and medications after the procedure10 25 
(GRADE of evidence: moderate; strength of recommenda-
tion: strong).
 ► Do not perform imaging and contrast studies routinely after 
the procedure, unless patients— during recovery—develop 
persistent chest pain, fever, breathlessness or tachycardia 
(GRADE of evidence: very low; strength of recommendation: 
weak).
 ► Ensure that patients are well and tolerating water on leaving 
the hospital4 (GRADE of evidence: low; strength of recom-
mendation: strong).
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 ► Suspect perforation when patients develop pain, breath-
lessness, fever or tachycardia.15 Transient chest pain is not 
uncommon following dilatation but persistent pain should 
prompt a CT scan with oral contrast to look for perfora-
tion54 (GRADE of evidence: low; strength of recommenda-
tion: strong).
A chest X-ray examination may show pneumothorax, pneu-
momediastinum, air under the diaphragm or a pleural effu-
sion but normal appearances do not exclude perforation. If 
clinical suspicion is high or if endoscopy examination raises 
the possibility of a deeper laceration than just mucosal, then 
ideally a CT scan with oral contrast should be performed. 
Conventional contrast studies are less sensitive and may miss 
small perforations.54–56 Moreover, CT can detect other compli-
cations, such as pleural effusions, pneumopericardium and 
pneumoperitoneum.57
 ► Perform endoscopic re-inspection if the patient becomes 
symptomatic while in the procedure room, in order to assess 
for the presence of perforation and to undertake treatment 
which may include immediate endoscopic stent placement6 
(GRADE of evidence: low; strength of recommendation: 
strong).
Iatrogenic perforation is a medical emergency. The patient 
should be assessed by an experienced physician and experienced 
surgeon in order to formulate an appropriate plan, which may 
include surgical, endoscopic or conservative management.4
 ► Provide patients with contact information for the on-call 
team should they experience chest pain, breathlessness 
or become unwell4 (GRADE of evidence: low; strength of 
recommendation: strong).
(b)Timing of next follow-up and procedure end points
The timing of subsequent dilatation sessions may depend 
on the degree of success of initial dilatation and the patient's 
response to the procedure. Patients often require multiple 
sessions, especially if the stricture has a narrow diameter or any 
complex features.58 In the majority of studies, a repeat proce-
dure was performed after 1 week and a subsequent follow-up 
at 2–4 weeks.31 59 In some patients, however, symptoms tend to 
recur rapidly following dilatation, hence they may require more 
frequent weekly or biweekly dilatations based on symptoms and 
stricture resolution.3 4
As a general rule, the last dilator size used in the previous 
session must be passed first. However, the degree of fibrosis 
and stricture healing is unpredictable and not all patients are 
expected to tolerate passage of the largest diameter dilator used 
during the previous session. Reassessment of stricture diameter 
is required and a smaller size dilator may be used if deemed 
appropriate.
Most patients respond well to oesophageal dilatation 
but outcomes are influenced significantly by the underlying 
pathology, with better clinical response rates achieved in peptic 
and post-surgical strictures than in caustic and post-radiation 
pathology.43
There is no consensus on the definition of end point for 
dilatation.  In one case  series of 321 patients, 98% of  those  in 
whom a 15 mm (45F) dilator was inserted, achieved clinical 
response over a mean follow-up period of 18.8 months.43 In one 
prospective study, all patients underwent dilatation to 15 mm 
then were randomised to either a subjective (end point is alle-
viation of dysphagia, n=19) or objective  (end point  is passage 
of 12 mm barium pill, n=15) group. Patients in the objective 
group had less recurrent dysphagia (P=0.02) and required fewer 
redilatation sessions (P<0.05) than the subjective group.59 The 
size of the oesophageal lumen will vary depending on the height 
and weight of the patient, and a 15 mm lumen end point is for 
someone of average size.
 ► Perform weekly or two-weekly dilatation sessions until easy 
passage of a ≥15 mm dilator is achieved along with sympto-
matic improvement31 43 59 (GRADE of evidence: moderate; 
strength of recommendation: strong).
A brief checklist is shown in figure 1. This may be used as a 
guide.
diseAse-sPecific considerAtions
This section discusses features of specific diseases, which may 
affect the dilatation procedure and patient outcomes.
Achalasia dilatation
Pneumatic balloon dilatation (PD) is one of a number of effective 
treatments for achalasia, which include surgical or endoscopic 
myotomy. However, the latter are outside the remit of this guide-
line.60 Bougie dilators are not used for achalasia dilatation.
 ► Perform dilatation with pneumatic balloons 30–40 mm in 
diameter starting at 30 mm in the first session to reduce 
the risk of complications5 19 61 (GRADE of evidence: high; 
strength of recommendation: strong).
The dilatation technique varies across different studies and 
there is no consensus in the literature on the optimal method 
of performing pneumatic dilatation for achalasia. The balloon is 
usually positioned at the oesophagogastric junction and inflated 
according to the manufacturers’ instructions for 1–3 min.
 ► Perform a second dilatation session 2–28 days later with a 
larger size balloon of 35 mm5 (GRADE of evidence: high; 
strength of recommendation: strong).
Most authors advocate a third session either routinely or 
in cases where symptoms remain (Eckardt score >3) with the 
cautious use of 40 mm balloon if possible. If the Eckardt score 
remains >3 after the third session, the treatment is usually 
considered to have failed.5 Patients with a recurrence of symp-
toms during follow-up may require further dilatation.5
 ► Consider repeat dilatation (after the initial series) during 
follow-up  to maintain symptom response5   (GRADE of 
evidence: high; strength of recommendation: strong). 
The procedure is effective in 90% of patients in the first year 
and this reduces to 86% in the second year.5 Up to one-third of 
patients may have recurrence of symptoms during 4–6 years of 
follow up.62 63 The vast majority can be successfully treated by 
repeat  dilatation,  achieving  remission  rates  of  up  to  97% and 
93% at 5 and 10 years, respectively.62
 ► Perform dilatation under endoscopic or fluoroscopic control 
based on clinician’s preference and local expertise64–66 
(GRADE of evidence: moderate; strength of recommenda-
tion: strong).
Fluoroscopic control is used in the majority of studies 
reporting safety and efficacy of balloon dilatation in achalasia; 
however, the safety of endoscopic control alone has been shown 
in a few studies.64–66 Comparative studies between the latter two 
approaches are lacking. Routine oesophagograms obtained after 
PD for achalasia did not reveal any clinically unsuspected perfo-
rations and no perforations were missed in cases that were not 
followed by oesophagograms.67 Impedance planimetry may be a 
tool that improves decision-making in dilating achalasia.68
 ► Consider proton pump inhibitor (PPI) therapy after dila-
tation as the technique has 10–40% rate of symptomatic 
gastro-oesophageal reflux disease (GORD) or ulcerative 
oesophagitis after treatment69–72 (GRADE of evidence: high; 
strength of recommendation: strong).
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PD does not preclude a subsequent myotomy. Similarly, 
PD may be performed for recurrence of dysphagia following 
myotomy.73–79
 ► Consider performing a water-soluble contrast swallow after 
dilatation to screen for perforation, but it is not essential67 80 
(GRADE of evidence: moderate; strength of recommenda-
tion: weak).
PD is contraindicated in patients with poor cardiopulmonary 
function, frailty or other comorbid illnesses preventing surgery, 
should an oesophageal perforation occur.81 Patients with hiatal 
hernia or oesophageal diverticulum have undergone PD safely by 
experienced operators.82
Peptic strictures
Peptic strictures requiring dilatation have been reported to 
occur in about 1–2% of patients with reflux oesophagitis, the 
proportion remaining relatively constant over the past three 
decades despite a rising incidence of reflux oesophagitis.83 This 
has been attributed to the widespread adoption of PPI therapy.84 
Between 40% and 60% of peptic strictures require only one dila-
tation,30 83 85 86 with the need for redilatation being highest in 
the subsequent 1–2 years.86 A recent snapshot of practice in the 
USA suggests that more than 80% of patients with peptic stric-
tures require only one dilatation.87 This may be because peptic 
strictures tend to be short and straight, and with the widespread 
use of PPIs for GORD this more recent survey of practice may 
reflect the fact that peptic strictures are becoming less severe. 
Patients with smaller stricture diameter and longer strictures are 
less likely to respond to dilatation and vice versa.32 58 85
It is clear that dysphagia in patients with reflux oesopha-
gitis may result from oesophagitis rather than stricture, and 
symptoms may improve with healing of oesophagitis using PPI 
figure 1 Stricture dilatation procedure checklist.
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therapy without the need for dilatation.88 In addition, oesoph-
agitis as well as stricture diameter contribute to the severity of 
dysphagia,89–91 and healing of oesophagitis in patients with stric-
tures is associated with a reduced need for redilatation.92 Finally, 
PPI therapy, but not H2 receptor antagonist treatment, reduces 
the need for, and frequency of, dilatation of peptic strictures 
after the initial dilatation.92–95
 ► Offer PPI therapy to patients with GORD and dysphagia, 
as this treatment has been shown to reduce the need for 
oesophageal dilatation83 84 89 92 (GRADE of evidence: high; 
strength of recommendation: strong).
 ► Offer PPI therapy after endoscopic dilatation for peptic 
strictures in order to reduce recurrence rate89 92–94 (GRADE 
of evidence: high; strength of recommendation: strong).
 ► Offer PPI therapy rather than H2 receptor antagonists, 
which are ineffective in reducing the need for repeat dila-
tation (stricture recurrence), less effective in healing of 
oesophagitis and in providing symptom relief from GORD 
and dysphagia89 92–95 (GRADE of evidence: high; strength of 
recommendation: strong).
The management of refractory peptic strictures will be 
discussed in the relevant section.
schatzki’s ring
Schatzki’s ring is an annular constriction at the gastro-oesoph-
ageal mucosal junction, covered on its proximal side by squa-
mous epithelium and distally by gastric mucosa.96 It was first 
appreciated on barium swallow radiology, provided the oesoph-
agus was adequately distended,97 occurring in 6–14% of barium 
swallow examinations and often asymptomatic.98 99 The natural 
history of asymptomatic Schatzki’s ring is unknown so it is not 
established whether treatment (for instance, with a PPI) is indi-
cated. Schatzki’s ring is less often seen at endoscopy100 unless 
the gastro-oesophageal junction is adequately distended by air 
insufflation. It is a common cause of intermittent dysphagia for 
solids and of food bolus obstruction: ‘Schatzki’s rule’ states that 
dysphagia is usual with ring diameters of ≤ 13 mm, and rarely 
occurs if the diameter exceeds 20 mm,101 with a ‘grey’ area in 
between where symptoms are less consistently observed.
Schatzki’s ring is associated with gastro-oesophageal 
reflux39 102  103 and with eosinophilic oesophagitis, even in the 
absence of other endoscopic oesophageal mucosal abnormali-
ties.100 102 This may explain why patients with rings and acid 
reflux (demonstrated by pH monitoring), and also unselected 
patients with Schatzki’s rings appear to have fewer recurrences 
after dilatation when receiving PPI therapy.39 104 Dysphagia due 
to Schatzki’s ring was relieved by PPI therapy without the need 
for dilatation in a small retrospective case series.105
Dilatation therapy for symptomatic Schatzki’s ring is directed 
toward achieving rupture of the ring; therefore, larger calibre 
dilators may be needed.101 There is robust evidence for the effi-
cacy of a single dilatation to 16–20 mm.106 Electrosurgical inci-
sion of the ring has been reported to be at least as effective in 
relieving dysphagia due to Schatzki’s ring as a single large calibre 
dilatation in randomised trials.107 Two studies suggest that inci-
sion may lead to longer remission of dysphagia than bougienage, 
proposing this treatment for patients with recurrence after a 
course of bougienage.108 109 Relapses still occur, but long-term 
PPI therapy (omeprazole 20 mg/day) significantly reduces the 
risk of relapse compared with placebo at up to 48 months of 
follow-up.39 104
Biopsy excision was shown to be effective and safe in a small 
feasibility study of 10 patients with dysphagia due to a Schatzki's 
ring (six of whom had previously undergone bougie or balloon 
dilatation). Complete endoscopic obliteration of the ring and 
improvement of dysphagia was achieved (using jumbo biopsy 
forceps) in all 10 patients during 379 days (range 63–496 days) 
of follow-up with no serious complications.110
 ► Do not offer dilatation for asymptomatic Schatzki’s rings 
incidentally discovered on diagnostic endoscopy or contrast 
studies (performed for unrelated indication)97–99 (GRADE of 
evidence: low; strength of recommendation: strong).
 ► Consider exclusion of eosinophilic oesophagitis by distal, 
mid and proximal oesophageal biopsies in symptomatic 
Schatzki’s ring100 102 (GRADE of evidence: moderate; strength 
of recommendation: strong).
 ► Offer a single dilatation session using graded dilatation to 
a relatively large diameter (16–20 mm) to treat dysphagia 
related to Schatzki’s ring39  106  111 (GRADE of evidence: 
moderate; strength of recommendation: strong).
 ► Offer PPI therapy after dilatation, as this reduces the risk 
of relapse of Schatzki’s ring39  104 (GRADE of evidence: 
moderate; strength of recommendation: strong).
 ► Consider electrosurgical incision as an effective alternative 
treatment to oesophageal dilatation for relieving dysphagia 
related to Schatzki’s ring108 109 112 (GRADE of evidence: high; 
strength of recommendation: strong).
In studies reporting this technique, the incision was performed 
using a standard needle-knife papillotome with a 5 mm cutting 
wire passed through the accessory channel of the endoscope. 
Three to four longitudinal incisions were performed radially to 
the junction of the base of the ring and the oesophageal wall.109 
Other experts recommend the use of standard endoscopic 
submucosal dissection (ESD) needle knife, IT knife or argon 
plasma coagulation.113 This procedure must be performed by a 
skilled operator who is familiar with the technique and uses it 
regularly (such as for ESD procedures).
Post-endoscopic therapy strictures
Oesophageal stenosis can occur after Endoscopic Resection or 
after Endoscopic Mucosal Ablation for oesophageal neoplasia.
Post-endoscopic resection (ER): stricture dilatation
ER procedures performed in the oesophagus include both endo-
scopic mucosal resection (EMR) and ESD.
It is generally accepted that once mucosal or submucosal resec-
tion of the oesophageal wall has encompassed greater than 75% 
of the circumference then symptomatic stenosis will occur.114–120 
Studies quote an OR for stricture formation of 44.2 (95% CI 4.4 
to 443.6) once more than 75% of the circumference has been 
resected119 and frequency of 49.7% when the length of resection 
was >40 mm.
For the majority of post-ER strictures, dilatation will resolve 
symptomatic dysphagia, although repeat procedures are often 
needed. Pouw et al121 showed that by using either Savary 
bougienage or balloon dilatation, all (84) patients who developed 
symptomatic strictures after stepwise radical ER were adequately 
treated by a median of 3 (IQR 2–6) dilatation sessions, supple-
mented by placement of a stent (n=2) or incision therapy (n=4). 
In 28 (33%) patients the stenosis was graded as severe since 
more than five endoscopic dilatations, stent placement or inci-
sion therapy were required.
Endoscopic balloon dilatation has been shown to be an effec-
tive and safe first-line intervention in patients with post -ER 
strictures, with a  reported  success  rate of 90% and a perfora-
tion rate of 0.3%122 in patients with symptomatic dysphagia 
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after EMR for early oesophageal cancer. Balloon dilatation has 
also been used to prevent strictures after ER. In one study, dila-
tation was performed after ER and repeated once a week until 
the mucosal defect was completely healed. The remaining 12 
cases were not treated and used as historic controls. Prophylactic 
dilatation  decreased  the  incidence  of  stricture  (59%  vs  92%, 
P=0.04); reduced the severity of stricture; and shortened the 
duration required for resolving the stricture (29 days vs 78 days, 
P=0.04) even when stricture developed.
The main complications associated with post-ER stricture 
dilatation are perforation, bleeding and a low risk of bacter-
aemia.118 120 The potential risk of perforation associated with 
dilatation of post-ER strictures is slightly higher (1.1%) that that 
seen in benign strictures (0.1%–1.02%).12 35 120 Also, strictures 
resistant to repeated dilatation do occur, and as in peptic stric-
tures, a fully covered self-expanding metal stent (SEMS) may 
need to be employed, but there are limitations, including chest 
pain and stent migration.121 Further large-volume studies are 
needed to clarify the long-term outcome.
 ► Inform patients of up to ~50% chance of developing symp-
tomatic stricture requiring endoscopic dilatation after ER 
either following EMR or ESD in any of the following situ-
ations: resection size >75% of the oesophageal circumfer-
ence; and a longitudinal resection length of >40 mm123 124 
(GRADE of evidence: high; strength of recommendation: 
strong).
 ► Offer dilatation for the management of symptomatic 
post-mucosal resection strictures32 35 122 123 125–127 (GRADE 
of evidence: moderate; strength of recommendation: strong).
 ► Inform patients that perforation rates of dilatation for 
post-ER strictures in the oesophagus can be up to 1.1%120 
(GRADE of evidence: moderate; strength of recommenda-
tion: strong).
 ► Offer fully covered SEMS in carefully selected patients for 
the dilatation of refractory strictures after ER121 128 (GRADE 
of evidence: low; strength of recommendation: weak).
Post-ER: stricture prevention
Endoscopic resection creates an ulcer which can be healed with 
PPI therapy based on previous studies on reflux oesophagitis and 
is known to reduce the risk of stricture formation.92  93 There 
are no comparative studies after endoscopic resection as PPI is a 
standard accepted treatment.
Endoscopic intralesional injections of steroids are applied 
based on the concept that inflammation and fibrosis after 
oesophageal ER are inhibited by the direct administration of 
steroids to the resection site. Takahashi et al129 carried out a 
randomised, controlled, open-label study to examine whether 
local steroid injection was an effective prophylactic treatment 
for oesophageal stenosis following extensive ESD. The authors 
found no difference in the frequency of stricture formation 
between the groups, but significantly fewer dilatation sessions 
were required in the steroid group than  in the control group 
(6.1  (95%  CI  2.8  to  9.4)  vs  12.5  (95%  CI  7.1  to  17.9); 
P=0.04).
Yamaguchi et al130 found that the stricture rate with oral pred-
nisolone (5.3%, 1/19) was significantly lower than in the control 
group (31.8%, 7/22) (P<0.0001). The steroids were started at 
30 mg/day on the third day after ESD, tapered gradually, and 
then discontinued 8 weeks later. Furthermore, the frequency 
of dilatation in the prednisolone group (mean 1.7, range 0–7) 
was significantly lower than in the control group (mean 15.6, 
range 0–48) (P<0.0001). Other studies have shown that using 
a reducing regimen of oral prednisolone in patients after large 
EMR or ESD reduces the need for repeated dilatation.131 132
Wen et al133 performed a single-centre randomised controlled 
trial and showed that the stricture rate and number of additional 
dilatations during a short-term follow-up period were signifi-
cantly lower in subjects treated by stent placement for 8 weeks 
immediately after ESD than in patients who were not treated 
with stents. Further studies are required to establish the bene-
fits and risks of SEMS in this setting—in particular, problems of 
postinsertion hyperplastic regenerative changes, which are diffi-
cult to distinguish from neoplastic residues.
Polyglycolic acid (PGA) is a synthetic compound that is 
completely degraded into a non-toxic degradation product, 
glycolic acid, over a period of 4–6 months in physiological 
conditions and has been employed in promoting tissue repair. 
Iizuka et al134 evaluated 15 patients after ESD in whom PGA 
sheets were placed, and oesophageal strictures occurred in only 
1/13 patients. These very early data show that PGA sheets may 
prevent oesophageal strictures after large-scale EMR or ESD in 
the oesophagus. Other tissue engineering techniques, such as 
transplantation of autologous oral mucosal epithelial cell sheets 
into ESD sites, are also being evaluated.135
 ► Offer PPI therapy after ER or ablation to reduce stricture 
occurrence92 93 (GRADE of evidence: low; strength of recom-
mendation: strong).
 ► Consider steroid injection at the resection site or oral pred-
nisolone therapy in patients at high risk after large EMR or 
ESD to reduce stricture formation130–132 136–139 (GRADE of 
evidence: moderate; strength of recommendation: weak).
 ► Offer fully covered SEMS in carefully selected patients for 
the prevention of refractory strictures after ESD of large 
lesions placing the stent at the same time as the first stric-
ture dilatation133 (GRADE of evidence: moderate; strength of 
recommendation: weak).
Post-ablative therapy: treatment and prevention
Field ablation is now accepted as an adjunctive treatment to 
endoscopic resection of oesophageal neoplasia and, in particular, 
neoplasia related to Barrett’s oesophagus (BO). Most interna-
tional guidelines now support this approach with much of the 
data supporting the use of radiofrequency ablation (RFA).140 
These treatments result in oesophageal ulceration which can 
be healed with PPI therapy based on previous studies on reflux 
oesophagitis, and PPI treatment is known to reduce the risk of 
stricture formation.92 93 There are no comparative studies after 
ablation as PPI is a standard accepted treatment.
Historically, photodynamic therapy (PDT) was the first-line 
ablation in patients with BO neoplasia. Owing to the toxicity 
and photosensitivity reactions associated with these agents its 
role is no longer advocated for the treatment of oesophageal 
neoplasia. One of the significant drawbacks of this technology 
was the high rate of stricturing in patients treated with PDT, 
which approached 36%.141 Most oesophageal strictures in the 
latter study were managed successfully through repeated dilata-
tions, with one patient requiring an oesophagectomy after dila-
tation-related perforation.
RFA has now been accepted as the 'gold standard' approach 
in patients with BO neoplasia. Ablation to a depth of 500 µm 
favours a reduced rate of stricture formation that is not the 
case with other ablation techniques. In a landmark randomised 
controlled trial, in which Shaheen et al142 compared RFA with a 
sham procedure, high disease eradication rates were seen and 
the stricture rate in the treatment group after a median of two 
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treatments was 6%. All patients underwent successful endoscopic 
dilatation (mean of 2.6 sessions). Data from the UK registry of 
patients undergoing RFA for BO neoplasia reported a similar 
stricture rate. Haidry et al143 showed an overall stricture rate 
requiring therapeutic dilatation of 9% (30 of 335 patients). All 
these cases were managed endoscopically with a mean of 1.3 
dilatations (range 1–6). Patients who underwent EMR before 
initiating RFA were more likely to develop strictures than those 
who did not (12% vs 5.9%; P=0.04).
The role of RFA for early squamous cell neoplasia has been 
controversial with early data supporting its use in well-selected 
patients,144 but it is associated with a higher stricture rate 
than with the same intervention in BO neoplasia. van Vilsteren 
et al144 showed a stricture rate of 23% and Bergman et al145 
a stricture rate of 14%. Data from the UK registry, where 20 
patients with early squamous neoplasia were treated with RFA, 
showed a stricture rate of 20%.146
 ► Inform patients that stricture formation requiring dilata-
tion is significantly higher in the following situations: after 
photodynamic therapy (PDT) (36%) compared with other 
forms of ablation141 147 148; where ER has preceded ablation 
(12% vs 6%)143; with use of higher doses of energy with 
RFA for Barrett's oesophagus (BO)149 150; and after RFA for 
early squamous cell neoplasia (14–23%)144–146 151 (GRADE 
of evidence: moderate; strength of recommendation: strong).
 ► Offer dilatation in patients with clinically significant 
stricture formation after RFA, with or without previous 
ER142 143 152 153 (GRADE of evidence: moderate; strength of 
recommendation: strong).
 ► Offer PPI therapy after ablation to reduce stricture occur-
rence92 93 (GRADE of evidence: low; strength of recommen-
dation: strong).
eosinophilic oesophagitis (eoe)
EoE is a common immune/antigen-mediated oesophageal 
disease characterised clinically by symptoms of oesophageal 
dysfunction and histologically, by eosinophil predominant 
inflammation.154 First described by Attwood and Straumann 
in  1993–94,155 156 EoE usually presents with dysphagia and 
is now the the most common cause of food bolus obstruction 
in patients under the age of 50 years.157 EoE is the the most 
common cause of spontaneous perforation of the oesophagus. It 
is the second most common benign disease of the oesophagus.158 
It is often underdiagnosed and yet 50 times more common than 
achalasia.158
Preliminary medical treatment and diet elimination for EoE
PPI, diet and topical steroids are all used as first-line treatments 
(in up to 50%).159 Dietary therapy with elimination of causative 
allergens, or topical corticosteroids may provide a durable long-
term solution.160 161 Topical steroids (such as fluticasone) and 
budesonide are very effective in the short term, but longer-term 
studies are needed.162
 ► Offer dilatation along with other forms of disease modi-
fication using diet, topical steroids or other drugs17 163–165 
(GRADE of evidence: moderate; strength of recommenda-
tion: strong).
 ► Start other treatments for EoE before dilatation if possible, 
and those may be continued afterwards to prevent or delay 
recurrence of symptoms163 164 166–169 (GRADE of evidence: 
moderate; strength of recommendation: strong).
 ► Offer preliminary topical steroids followed by dilatation 
as this is more cost-effective than using dilatation alone as 
first-line treatment164 170 (GRADE of evidence: moderate; 
strength of recommendation: strong).
Indications for dilatation in EoE
The indications for dilatation in EoE include established tight 
stricture, narrow calibre oesophagus, food bolus obstruction and 
failure of symptoms to respond to diet or drugs.8 16 171 Dilata-
tion of the oesophagus is now a standard treatment for EoE, 
along with other forms of chronic disease modification using 
diet, topical steroids or other drugs.17 163–165 Other treatments 
for EoE should be started before dilatation if possible, and 
continued afterwards to prevent or delay recurrence of symp-
toms.163 166–170 172 A recent randomised controlled study by Kavitt 
et al170 has shown that preliminary topical steroids followed by 
dilatation is more cost-effective than using dilatation as the first 
treatment. In some patients, dilatation can be used as the only 
treatment.17 162 164 170 173–175 However, caution should be exer-
cised with tight strictures of <7 mm calibre.170
 ► Offer dilatation as first line treatment in patients with 
acute symptoms such as food bolus obstruction and daily 
dysphagia17 164 173–175 (GRADE of evidence: moderate; 
strength of recommendation: strong).
 ► Offer dilatation to patients with established tight stricture, 
narrow calibre oesophagus and those who do not respond to 
diet or drugs8 16 163 168 (GRADE of evidence: high; strength of 
recommendation: strong).
Risks and complications of dilatation in EoE
Dilatation of EoE is no more dangerous than dilatation for 
other oesophageal diseases (such as peptic stricture or acha-
lasia), and the perforation rates are similar if safe techniques 
and flexible endoscopy are employed by experienced oper-
ators.17 158 162 163 176–178 Mucosal tears and associated minor 
bleeding are common after dilatation of EoE (8%), and can be 
managed conservatively.16 171 176 177
The risk of postprocedural chest pain is particularly common 
after EoE dilatation and may last for up to 48 hours.169 176 179 
Patients should be warned about this possibility, and the need 
to take fluids and analgesia along with their maintenance EoE 
therapy.
 ► Reassure patients that dilatation of EoE is no more dangerous 
than dilatation for other oesophageal diseases, and the perfo-
ration rates are similar16 17 163 174 176–178 (GRADE of evidence: 
high; strength of recommendation: strong).
 ► Inform EoE patients that chest pain after dilatation is 
common17  169  176 (GRADE of evidence: high; strength of 
recommendation: strong).
Follow-up treatment after dilatation in EoE
A good clinical outcome is dysphagia resolution and avoidance 
of food bolus obstruction after dilatation.8 16 177 Most experts 
recommend gradual slow dilatation with sessions separated by 
3–4 weeks and aim for a diameter of 16–18 mm, if possible.180 
Repeat dilatation should be offered if symptoms of severe 
dysphagia recur or if a symptomatic stricture is diagnosed during 
follow-up.8 16 177 Symptom response after initial dilatations 
(about three sessions over several weeks) usually lasts for up 
to 1 year.167  169 Dilatation of the oesophagus in EoE may be 
repeated if needed.163 167 174 181
Maintenance treatment with either topical steroid or dietary 
elimination should continue after dilatation of EoE. A repeat 
endoscopy is recommended at 6–12 weeks.174 177
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 ► Inform patients that symptom response after dilata-
tion usually lasts up to 1 year167  169 (GRADE of evidence: 
moderate; strength of recommendation: strong).
 ► Repeat dilatation if needed167 171 174 181 (GRADE of evidence: 
high; strength of recommendation: strong).
Method of dilatation in EoE
There are no credible data comparing balloon with bougie dila-
tation in EoE, but most observers prefer balloon to reassure the 
operator that a perforation is not occurring.16 174 179 181 Otherwise 
the technique remains the same as for other types of stricture.
Use of distensibility measure to guide dilatation in EoE
Endoscopic Functional Luminal Imaging Probe (EndoFLIP, 
Crospon, Galway, Ireland) is used in some specialist centres to 
measure compliance and distensibility. EndoFLIP and Balloon 
pull through techniques may help in judging the optimal calibre 
to dilate to but require further study.166 182 183 These tech-
niques are innovative, safe and seem effective. More research 
on their cost-effectiveness is warranted. The availability and 
cost-effectiveness will be the main considerations before 
formulating recommendations for their routine use in clinical 
practice. A recent study has shown that endoscopy has a sensi-
tivity of only 25% in detecting narrowed oesophagus ≤15 mm 
in diameter among patients with EoE compared with barium 
radiology.184
 ► Consider the use of special techniques such as EndoFLIP and 
Balloon pull through to judge the optimal calibre and posi-
tion of dilatation182 183 (GRADE of evidence: low; strength of 
recommendation: weak).
Postoperative strictures
Frequency and situation
All surgical interventions have the potential for fibrotic stric-
turing at the anastomotic site as a complication. Oesophagec-
tomy with oesophago-gastrostomy for oesophageal or gastric 
cardia malignancy can lead to stricturing in 4%185 to 66%.186 
These strictures tend to be short and straight, but occasionally 
can be complicated.187 188 Methods for prevention of stricturing 
by surgical technique to maximise vascularisation of the anasto-
mosis is a key strategy in the prevention of oesophageal anasto-
motic strictures.185 186 188–191
Fundoplication for GORD, both partial and total, is also 
associated with postoperative dysphagia, affecting 5–43% of 
people.192  193 Mechanisms behind this include a tight wrap, a 
slipped wrap and paraoesophageal hernia.194  195 Partial wraps 
are less likely to cause significant postoperative dysphagia than 
a Nissen.195  196 Intraoperative evaluation of the oesophagus—
for example, using the EndoFLIP device, could allow the oper-
ator to determine the length of wrap and optimal tightness of 
the gastro-oesophageal junction during the fundoplication 
procedure,197 thereby reducing postoperative dysphagia and/or 
the need for dilatation.
Preliminary medical treatment and investigations
Nutritional supplementation, particularly in patients with 
cancer, and PPI therapy following bariatric surgery198 are 
important. Specific investigations, including endoscopy and 
barium swallow, are helpful.
 ► Consider performing upper GI endoscopy, manometry, pH 
studies and barium swallow first in patients with persis-
tent dysphagia post-fundoplication surgery, in order to 
assess the integrity of the wrap and understand the cause 
of dysphagia prior to dilatation or repeat surgery194  195 
(GRADE of evidence: low; strength of recommendation: 
weak).
Methods of dilatation of postoperative strictures
Treatment of postoperative stricture has used both bougienage188 
and balloon dilatation, both under direct endoscopic visualisa-
tion185  199 or with fluoroscopy,200 and no data exist to show 
which is optimal.186
Symptoms improve after the first dilatation session in up 
to 43% of individuals185 and therefore repeat dilatation is the 
norm. Typically, a median of three sessions is used before satis-
factory relief of dysphagia is achieved.189
Treatment success is difficult to define, limiting comparisons 
between studies but may be obtained in between 62%195 and 
100%.189 Delayed gastric emptying appears to be an additional 
risk factor for stricture formation, and treatment of this by pylo-
roplasty or pyloromyotomy may help to reduce the frequency 
of dilatation sessions required to achieve successful treatment of 
anastomotic stricture.199
In the post-fundoplication setting, dilatation of the lower 
oesophageal sphincter typically requires 30–40 mm balloons, 
similar to those used in the management of achalasia.194 Success 
can be achieved in approximately two-thirds of patients, 
although non-responders may require revisional surgery.201
 ► Consider treatment of concurrent delayed gastric emptying 
in order to reduce the need for redilatations199 (GRADE of 
evidence: low; strength of recommendation: weak).
 ► Consider the use of balloon dilatation to 30–40 mm (as with 
achalasia) in patients with post-Nissen dysphagia194 (GRADE 
of evidence: low; strength of recommendation: weak).
Use of supplementary methods
The use of steroid injection (0.5 mL aliquots of triamcinolone 
40 mg/mL to four quadrants) has been evaluated in anastomotic 
strictures in a randomised double-blind study and found to be 
safe when injected with a 4 mm-long, 23-gauge needle imme-
diately before bougie dilatation of anastomotic strictures.202 In 
this study, the steroid arm appeared superior in the length of 
time required between dilatation sessions (108 days vs 42 days 
in the saline group), and the total number of dilatation sessions 
required (two in the steroid group versus three in the saline 
group). However neither of these outcomes reached signifi-
cance. Steroid-treated patients with stricture were found to 
have significantly more complications, specifically oesophageal 
candidiasis.
Needle knife incision has also been evaluated in refractory 
strictures and in the primary treatment of anastomotic stric-
tures.203 204 In experienced hands, this technique is as safe as 
conventional dilatation methods, but evaluation of the success 
of this treatment strategy is more variable. Primary treatment 
with incisional therapy appears to  confer no significant advan-
tage over bougie dilatation in the mean number of dilatations 
or overall success rate at reducing symptoms of dysphagia.203 
Specific methods used for incisional therapy include either an 
endoscopic needle knife or an ‘IT’ knife, incising in four quad-
rants with the aid of a transparent cap, which enhances the safety 
of the procedure. The procedure is best done by an operator 
who is familiar with techniques of incision through experience 
with ESD or endoscopic retrograde cholangiopancreatography. 
Incisional therapy appears to maintain luminal patency, at 12 
months’  follow-up  in  61.5%  of  cases  compared  with  19.8% 
in controls who underwent continued endoscopic balloon 
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dilatation,205 and so has a role in the treatment of unresponsive 
anastomotic stricture.
 ► Use steroid injections (0.5 mL aliquots of triamcinolone 
40 mg/mL to the four quadrants) to reduce the frequency 
of repeat dilatations in anastomotic strictures refractory to 
initial dilatation approaches. Use a 4 mm-long, 23-gauge 
needle immediately before bougie dilatation while leaving 
the needle in for at least 1 min to minimise leakage of the 
drug and ensure delivery of the full dose to the target 
area113 202 (GRADE of evidence: moderate; strength of recom-
mendation: weak).
 ► Consider using needle knife incision for anastomotic stric-
tures as an alternative to dilatation203 205–207 (GRADE of 
evidence: moderate; strength of recommendation: weak).
Risks and follow-up
After treatment of postoperative strictures, complication rates 
such as bleeding or rupture have been reported in up to 30% of 
cases,200 208 but perforation with mediastinal leakage appears to 
be no more common than in other types of strictures.
There appears to be no evidence to warrant surveillance of 
patients postoperatively for anastomotic stricture.
Post-radiation strictures
Radiotherapy treatment has revolutionised the management 
of most solid organ malignancies, but may induce stricturing 
of the oesophagus. The risk of stricturing can be anticipated 
before radiotherapy in patients with greater tumour inva-
sion (T-score) and greater circumferential involvement.209–211 
Radiotherapy induces tissue ischaemia, fibrosis and subse-
quent oesophageal stenosis. In contrast to other oesophageal 
strictures, the fibrosis often affects the tissues surrounding the 
oesophagus, creating a non-compliant mediastinum. As a conse-
quence, radiation strictures are frequently refractory to dilata-
tion and progressive. The risk is increased with higher radiation 
doses.212–217 Furthermore, radiotherapy with concurrent chemo-
therapy increases the likelihood of stricture217 218 and is a cause 
of completely obstructed oesophagus,.212 219–221 Prior insertion 
of a gastrostomy should be considered to aid nutrition in already 
malnourished individuals and this offers an additional conduit 
through which dilatation attempts of subsequent oesophageal 
strictures can be made. Where antegrade passage of a guidewire 
is unsuccessful, a retrograde attempt through the gastrostoma 
can be made using catheter and guidewire under fluoroscopic 
control.
The endoscopic CARD approach can be considered in patients 
with a completely occluded oesophagus. In most circumstances, 
this requires a general anaesthetic, although conscious sedation 
has also been used.218 222 A CT scan is also recommended to 
exclude nearby vessels.223
Visualisation of the proximal aspect of the stricture is under-
taken by insertion of an antegrade endoscope. A second endo-
scope is inserted through the gastrostomy site and the stricture is 
trans-illuminated in order to identify the now obstructed lumen. 
Typically, a guidewire is passed from the distal oesophagus prox-
imally under fluoroscopic guidance, puncturing through the 
stricture and then removed per-orally.209 212 219 222–224 A needle 
knife,225 straight catheter223 or EUS fine aspiration needle223 225 226 
has also been shown to be effective at traversing the stricture by 
incision. Biplanar fluoroscopy or cone-beam CT may be used to 
facilitate an axial alignment of the endoscopes and needles and 
reduce the risk of perforation. Once a guidewire has been passed 
a bougie or balloon can dilate to 12–15 mm.219–221 223 224 226–229 
In some patients, the placement of a temporary (up to 1 month) 
fully covered SEMS is necessary to maintain the luminal patency 
with or without a nasogastric tube for feedig.223
No large studies have been undertaken to evaluate the use of 
the CARD procedure, and it should be regarded as a last resort 
for use in expert hands only. Evidence from case series suggests 
it is safe, with no patients requiring emergency surgical inter-
vention.223 The majority of larger series suggest good success 
(defined as discontinuation of percutaneous endoscopic gastros-
tomy feeding), although in most instances, repeated dilatation is 
still required every 2–3 months.212 219 223
 ► Consider a combined anterograde and retrograde dilata-
tion (CARD) or rendezvous approach under general anaes-
thetic as an alternative to surgery in the treatment of the 
completely obstructed oesophagus, where local expertise 
is available209  212  218  219  221  222  225–228 (GRADE of evidence: 
moderate; strength of recommendation: weak).
 ► Use fluoroscopic guidance to assist with the rendezvous 
procedure209  212  218  219  221  222  225–227 (GRADE of evidence: 
moderate; strength of recommendation: strong).
 ► Use a guidewire to navigate through the obstruction 
when using the CARD approach to re-establish luminal 
patency209 212 219 222 225 (GRADE of evidence: low; strength of 
recommendation: strong).
 ► After gaining luminal patency using the CARD procedure, 
perform subsequent dilatation using either balloon224 226 229 or 
bougie212 219–221 228 (GRADE of evidence: moderate; strength 
of recommendation: strong).
caustic strictures
Oesophageal injury can be caused by ingestion of caustic 
substances. Alkalis are the the most common caustic agents 
ingested in Western countries, while acid ingestion is more 
common in developing countries, such as India. Caustic oesoph-
ageal injury can lead to the lower oesophageal sphincter pressure 
becoming impaired, which in turn leads to gastro-oesophageal 
reflux that can worsen stricture formation.230 231
After initial radiological assessment, an upper gastrointestinal 
tract endoscopy, with gentle air insufflations or preferably with 
CO2, should be considered after caustic ingestion within the first 
12–48 hours to determine prognosis and management, including 
oesophageal stricture formation and subsequent requirement 
for dilatation.232 Contraindications to endoscopy include radio-
logical suspicion of perforation or burns to the supraglottic and 
epiglottic areas. A CT grading system for caustic lesions has been 
proposed, but there is insufficient evidence to demonstrate its 
widespread utility.233 234
 ► Perform upper gastrointestinal tract endoscopy within the 
first 12–48 hours after caustic ingestion235–238 (GRADE of 
evidence: moderate; strength of recommendation: strong).
Several techniques have been used in an attempt to prevent 
stricture formation. These techniques include oral steroids,239 240 
antibiotics, mitomycin C and intraluminal stents,241 but there is 
limited evidence on outcomes.
Late management makes dilatation more complex owing to 
fibrosis in the oesophageal wall. Dilatation can be carried out 
with either bougie or balloon dilators. There is no clear advan-
tage of one technique over another.126 242–246 The Savary-Gilliard 
type was used in the majority of studies reporting on efficacy 
of bougie dilatation and is preferred by some practitioners in 
consolidated and fibrotic strictures.
 ► Ensure timely management of oesophageal strictures 
with dilatation as this plays a key role in affecting patient 
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outcomes242–246 (GRADE of evidence: moderate; strength of 
recommendation: strong).
Dilatation is more hazardous between 1 and 3 weeks after 
injury and some avoid this time interval. From approximately 
week 3, scar retraction begins, resulting in stricture formation. 
The time interval between dilatations varies in published reports 
but should be less than 2–3 weeks. The number of sessions 
required to achieve the desired outcome varies; usually three or 
four are required but the number can be significantly higher.
The perforation rate for caustic strictures is higher than 
the standard benign oesophageal stricture dilatation rate with 
anything from 0.4% up to 32% recorded in the literature. The 
complication rate is lower when performed by those with more 
experience, and reported to be 4.5%.
 ► Consider avoiding dilatation within 3 weeks of initial caustic 
ingestion242 246 (GRADE of evidence: low; strength of recom-
mendation: weak).
 ► Consider a time interval between dilatations of 
<2 weeks246 247 (GRADE of evidence: very low; strength of 
recommendation: weak).
Refractory strictures are more common in caustic ingestion. 
Management has been reported with intralesional steroid injec-
tion or topical mitomycin C at the time of dilatation, tempo-
rary stent placement, biodegradable stents and a suspended 
oesophageal silicone prosthesis. If oesophageal dilatation fails 
then surgical resection can be considered. There is no consensus 
for the optimum management of these strictures.245 248–252
refractory strictures
A stricture should be considered refractory after an inability to 
maintain  a  luminal  diameter of   ≥14 mm after  five  sequential 
dilatation sessions 1–2 weeks apart or maintain the target diam-
eter for 4 weeks once it has been reached.253 Refractory strictures 
are rare and challenging. Before embarking on any particular 
management the clinician and patient should be aware of the 
poor level of data for the outcomes and risks of most techniques.
 ► Inform patients about the lack of good quality evidence for 
best approach to treatment of refractory strictures (GRADE 
of evidence: low; strength of recommendation: strong).
 ► Consider discussion with, and/or referral to, centres with 
expertise in treatment and follow-up of patients with refrac-
tory strictures (GRADE of evidence: low; strength of recom-
mendation: weak).
 ► Ensure optimal management of ongoing inflammation with 
high dose PPI therapy before defining a stricture as refrac-
tory83 84 89 92 (GRADE of evidence: high; strength of recom-
mendation: strong).
 ► Consider alternative neuromuscular causes in patients with 
ongoing dysphagia despite a seemingly adequate oesoph-
ageal diameter126 (GRADE of evidence: low; strength of 
recommendation: strong).
Complex strictures (>2 cm, angulated, irregular, severely 
narrowed) of the following aetiologies are most often implicated 
in refractory strictures: anastomotic, radiation induced, caustic, 
post-ablative therapy.33
Method of dilatation
No trials have compared types of dilators for refractory strictures.
 ► Use fluoroscopic guidance during dilatation of refractory 
oesophageal strictures126 (GRADE of evidence: very low; 
strength of recommendation: weak).
 ► Use either bougie or balloon dilators with the decision indi-
vidualised on a case by case basis dependent on the nature 
(length, location, cause) of the stricture126 (GRADE of 
evidence: low; strength of recommendation: weak).
Intralesional steroid therapy
Intralesional steroid therapy involves the injection of 0.5 mL 
aliquots of 40 mg/mL triamcinolone to all four quadrants of the 
stricture. Experts advocate predilatation, although there are no 
studies directly comparing this with postdilatation injection. Two 
randomised controlled trials in patients with refractory stric-
tures of mixed, but mostly peptic, aetiology, have demonstrated 
benefit, with reduction in the number of repeat dilatations and 
an increase in the dysphagia-free period.254 255 Results have been 
disappointing for refractory strictures of other aetiologies, with 
randomised controlled trials failing to show improvement in 
anastomotic202 and caustic256 aetiologies. In addition, an increase 
in complications was seen in the steroid-treated patients.202
 ► Use intralesional steroid therapy combined with dilata-
tion in refractory strictures with evidence of inflamma-
tion (macro- or microscopically) on the assumption that 
anti-reflux therapy has been maximised previously with 
no benefit202 254–256 (GRADE of evidence: high; strength of 
recommendation: strong).
Incisional therapy
Use of a needle or IT knife to perform radial incisions of refrac-
tory strictures parallel to the longitudinal axis of the oesoph-
agus has been evaluated. The procedure is performed under 
direct visualisation with or without a transparent cap. For 
circumferential strictures, incisions in the four quadrants may 
be most effective. The outcomes are best for short strictures 
(<1.5 cm).257 Longer strictures may initially respond, but most 
will require re-treatment.258
 ► Consider incisional therapy in patients with refractory 
Schatzki’s rings and anastomotic strictures at centres expe-
rienced in the use of such techniques257 258 (GRADE of 
evidence: very low; strength of recommendation: weak).
Stents
The benefit of self-expanding removable stents has been demon-
strated in a recent systematic review and meta-analysis, with 
complete relief of dysphagia in approximately 40% (median 
follow-up 0–1281 days over the 18 included studies).259 The 
majority of refractory strictures will respond to placement of 
between 4 and 8 weeks, although longer periods of up to 3 
months may be required.259 It is recommended that stents should 
not be left in longer than this owing to the risk of embedding. 
Recurrence rates of refractory strictures remain as high as 69% 
after stent removal, particularly in patients with long strictures 
(>7 cm),260 illustrating the difficulties in achieving a satisfactory 
long-term outcome.
In trials directly comparing metal and plastic stents, outcomes 
were more favourable with metal stents, with lower migra-
tion rates and need for re-intervention.261 262 Stent migration 
is a considerable problem with both stent types, occurring in 
approximately 30% of cases.259 Stent placement is associated 
with adverse events (chest pain, bleeding, perforation, aspira-
tion pneumonia) in 20% and thus patients should give consent 
accordingly.259 Use of partially or uncovered metal stents must be 
avoided owing to risk of embedding of the stent in the oesopha-
geal wall, which may preclude safe removal.
 ► Offer temporary placement of fully covered self-expanding 
removable stents in patients where previous methods have 
been unsuccessful in maintaining adequate oesophageal 
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patency259–265 (GRADE of evidence: low; strength of recom-
mendation: weak).
 ► The optimum duration of stent placement is usually between 
4 and 8 weeks, but may vary depending on stricture aeti-
ology and length, and type of stent264 (GRADE of evidence: 
very low; strength of recommendation: weak).
Single biodegradable stent placement appears to be only 
temporarily effective in the majority of patients with refractory 
benign oesophageal stricture.266 267 It can, however, reduce the 
frequency of serial dilatation in selected patients. In the largest 
study to date, sequential placement of a first, second and then 
third biodegradable stent resulted in a median dysphagia free 
period  of  90,  55  and  106  days,  respectively.267 No patients 
were dysphagia free at the end of the study, suggesting that this 
strategy is not effective for long-term dysphagia relief.
 ► Consider biodegradable stent placement to reduce the 
frequency of dilatation in selected cases266 267 (GRADE of 
evidence: low; strength of recommendation: weak).
Options for failed stricture resolution
Self-dilatation is safe and effective for short, proximal stric-
tures.268–270 For appropriate, well-trained patients willing to 
undertake this, it appears to be well tolerated, can prevent 
surgery and the burden of repeated hospital visits.268–270
 ► Consider teaching selected, self-motivated patients, with 
short proximal strictures to self-bougienage268–270 (GRADE 
of evidence: very low; strength of recommendation: weak).
 ► Offer surgery to patients who do not respond or are intol-
erant to other measures271 272 (GRADE of evidence: low; 
strength of recommendation: weak).
A brief summary of disease-specific considerations is provided 
in box 1.
economic imPlicAtions
Oesophageal stricturing has a significant impact on quality 
of life owing to both dysphagia symptoms and the need for 
repeated dilatation. Quality of life scores are often further 
affected by underlying diagnosis, such as head and neck 
cancer.273 274
No studies have investigated the cost-effectiveness of dila-
tation, but it is generally appreciated that bougienage has 
better economic benefits than balloon dilatation. This is 
owing to the absence of symptomatic or endoscopic differ-
ence between the two modalities in addition to the non-signifi-
cant difference in the need for repeated treatments. Hence the 
consumable costs of disposing of and replacing TTS balloons 
outweigh those of reusable Savary bougies. Furthermore, extrap-
olation from studies in the lower GI tract comparing balloon 
versus bougienage in the management of postoperative anasto-
motic strictures has shown similar findings (median cost €680 
vs €22.30; P<0.001).275 These considerations obviously require 
to be balanced with expertise, local availability and endoscopist 
preference, for example, to allow direct visualisation during the 
dilatation procedure.
Use of oesophageal stenting is outside the remit of these guide-
lines, but it may also be considered in cases where repeated dila-
tation is required and can be considered to add cost-effectiveness 
when two or more dilatations are avoided.276
There are no other special economic effects of these guidelines, 
as they are a formalisation of current practice with the evidence 
base, and we do not advocate any changes or new directions in 
care that have a major economic impact.
Audit of effectiveness
Items that could be subject to audit to establish good clinical 
standards of oesophageal dilatation include:
 ► Completeness of consent forms with clear documentation in 
each section (including procedure risks and benefits).
box 1 considerations in specific disease areas
Achalasia:
 ► Use pneumatic balloons 30–40 mm in diameter
 ► Start at 30 mm in the first session to reduce the risk of 
complications
 ► Perform a second dilatation 2–28 days later with a larger 
balloon (usually 35 mm)
 ► Consider PPI therapy after dilatation
Peptic strictures:
 ► PPI therapy long term
 ► No role for H2 receptor antagonists
schatzki’s ring:
 ► Asymptomatic=no dilatation
 ► Symptomatic=single session (aim for 16–20 mm diameter)
 ► Exclude eosinophilic oesophagitis
 ► Consider PPI
 ► Consider needle knife incision if dilatation not effective
Post-endotherapy:
 ► Perforation risk may be higher (around 1.1%)
 ► Consider steroid injection to reduce risk of stricture  
formation
 ► Offer PPI to reduce risk of recurrence
eosinophilic oesophagitis:
 ► Consider additional treatments (PPI, steroids, elimination 
diet)
 ► Aim for histological remission
 ► Consider dilatation in narrow calibre oesophagus or failure of 
medical treatment in the absence of a visible stricture
 ► Inform patients that chest pain is common
Postoperative:
 ► Post-fundoplication:
 – Assess wrap integrity with upper endoscopy, barium 
swallow, manometry and pH impedance
 – Use pneumatic balloon 30–40 mm as for achalasia
 ► Anastomotic:
 – Consider concomitant steroid injection in four quadrants
 – Consider needle knife incision as an alternative to 
dilatation
Post-radiation:
 ► Consider CARD in completely obstructed oesophagus
caustic:
 ► Careful evaluation as usually complex
 ► Dilatation not advised in first 3 weeks after ingestion
refractory:
 ► Ensure optimal dose PPI and control of inflammation
 ► Consider:
 – Discussion with expert centres
 – Alternative causes/underlying pathology
 – Concomitant steroid injection four quadrants
 – Needle knife incision
 – Fully covered SEMS as temporary measure 4–8 weeks
 ► Offer patient the option of self-dilatation
CARD, combined anterograde retrograde dilatation; PPI, proton pump 
inhibitor; SEMS, self-expanding metal stent.
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 ► Success rate, comfort scores, re-intervention rate (number of 
dilatations per patient), complication rates, 30-day readmis-
sion rates and 30-day mortality rates.27
 ► Using a standard scoring system for dysphagia (such as 
Ogilvie, Dakkak and Bennett, etc)  in >90% of patients  to 
provide an objective measure of the efficacy of the thera-
peutic intervention.27
 ► Timeliness of follow-up serial sessions for endoscopic dilata-
tion (within 2 weeks).33 59
 ► Perforation rates. The overall perforation rate following 
dilatation should be <1% for benign strictures27 and 1–2% 
for achalasia.19 20
AreAs for future reseArch
 ► Identification of the learning curve, assessment parameters 
required and direct observation of procedure or skills design 
for formative and summative assessments for trainees under-
taking dilatation.
 ► The number of dilatation procedures performed each year 
required to achieve competency and maintain skill.
 ► Direct cost-effectiveness comparison between balloon and 
bougie dilators.
 ► Assessment of the optimal interval between repeat dilata-
tions for tight, complex or refractory strictures.
 ► Available data on the role of acid suppression, proton pump 
inhibition, elimination diet and steroids in EoE are limited 
by variation in clinical practice and reported outcomes. 
Randomised controlled trials are needed to identify the 
optimum treatment to prevent oesophageal strictures in 
EoE.
 ► Clarification of the role of steroids and other methods in 
reducing the incidence and severity of post-ER strictures. 
There is an ongoing phase III clinical trial comparing oral 
steroid versus local steroid injection therapy for the preven-
tion of oesophageal stricture after ESD.277
 ► Research into the true incidence of refractory strictures 
with details of aetiology and comparative outcomes after 
different treatments.
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